










1 Article

2 Beyond vaccination: A Cross-Sectional Study of the importance of Be- 3 havioral and Native Factors on COVID-19 Infection and Severity.

4 Hani Amir Aouissi ¹, , Mostefa Ababsa ¹, , Carlos M. Leveau ^{2,3}, , Alexandru-Ionut Petrisor ^{4,5}, , Artur Słomka ⁶, ,
5 Mohamed Seif Allah Kechebar ¹, , Jun Yasuhara ⁷, , Loïc Epelboin ^{8,9},  and Norio Ohmagari ^{10,11}, 

6 ¹ Scientific and Technical Research Center on Arid Regions (CRSTRA), Biskra 07000, Algeria; aouissi.amir@gmail.com (H.A.A.);
7 mostefa.ababsa@gmail.com (M.A); kechebarmohamed@yahoo.fr (M.S.A.K).

8 ² Consejo Nacional de Investigaciones Científicas y Técnicas: Lanús, Argentina; cmleveau@hotmail.com

9 ³ Universidad Nacional del Lanús: Lanús, Buenos Aires, Argentina.

10 ⁴ Doctoral School of Urban Planning, Ion Mincu University of Architecture and Urbanism, 010014 Bucharest, Romania;
11 alexandru_petrisor@yahoo.com

12 ⁵ National Institute for Research and Development in Tourism, 50741 Bucharest, Romania.

13 ⁶ Department of Pathophysiology, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum in Bydgoszcz,
14 85-067 Bydgoszcz, Poland; artur.slomka@cm.umk.pl

15 ⁷ Center for Cardiovascular Research, The Abigail Wexner Research Institute and The Heart Center, Nationwide Children's Hospi-
16 tal, Columbus, OH, USA; jun.yasuhara@nationwidechildrens.org

17 ⁸ Infectious and Tropical Diseases Department, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana; [epel-
18 boincrh@hotmail.fr](mailto:epel-boincrh@hotmail.fr)

19 ⁹ Centre d'Investigation Clinique (CIC INSERM 1424), Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana.

20 ¹⁰ Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan;
21 nohmagari@hosp.ncgm.go.jp

22 ¹¹ AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.

23 * Corresponding author: aouissi.amir@gmail.com (H.A.A); Tel.: +213662387144

24 **Abstract:** The COVID-19 pandemic has a major impact on a global scale. Understanding the innate and lifestyle-related factors
25 influencing the rate and severity of COVID-19 is important for making evidence-based recommendations. This cross-sectional
26 study aimed at establishing a potential relationship between human characteristics and vulnerability/resistance to SARS-CoV-2. We
27 hypothesize that the impact of virus is not the same due to cultural and ethnic differences. A cross-sectional study was performed
28 using an online questionnaire. The methodology included a development of a multi-language survey, expert evaluation and data
29 analysis. Data was collected using a 13-item pre-tested questionnaire based on a literature review. Data was statistically analyzed
30 using the logistic regression. For a total of 1125 respondents, 332 (29.5%) were COVID-19 positive, among them 130 (11.5%) re-
31 quired home-based treatment, and 14 (1.2%) intensive care. The significant factors included age, physical activity and health status
32 all found to have a significant influence on the infection ($p < 0.05$). The severity of infection was associated with preventive
33 measures and tobacco ($p < 0.05$). This suggests the importance of behavioral factors compared to innate ones. Apparently, the indi-
34 vidual behavior is mainly responsible for the spread of the virus. Adopting a healthy lifestyle and scrupulously observing preven-
35 tive measures including vaccination would greatly limit the probability of infection and prevent the development of severe
36 COVID-19.

37 **Keywords:** COVID-19; vaccines; public health; preventive measures; behavior; infectious diseases.

38

39

40

41

42

43

44

45

46

47

48

49

50 1. Introduction

51 1.1 Background

52 According to the WHO (World Health Organization), several coronaviruses (CoVs) have been reported since 2002.
53 The coronavirus responsible for the 2019 pandemic was named SARS-CoV-2 by ICTV (International Committee on
54 Taxonomy of Viruses) due to its similarity to SARS viruses [1].

55 In the end of 2019, a novel beta coronavirus was identified in China's Hubei province, at Wuhan [2]. By that time, the
56 virus has spread and disrupted all aspects of humans worldwide. The symptoms of severe acute respiratory syn-
57 drome coronavirus 2 are similar to those of previously known coronavirus infections including fever, dry cough, and
58 fatigue; however, the SARS-CoV-2 has a higher spreading nature [3,4]. It has largely surpassed MERS and SARS in
59 terms of both spatial range of epidemic areas and number of infections. The global health crisis experienced has posed
60 a significant threat to public health [5].

61 According to the WHO's weekly operational update on COVID-19 of 13 December 2021, there are almost 273 million
62 confirmed cases and 5,34 million related deaths worldwide [6]. The consequences were serious, especially at the start
63 of epidemic, given the lack of information and means to fight this virus [7]. Across the world, a significant number of
64 proactive measures have been adopted, including distance education, banning international traveling, and the cam-
65 paign encouraging everyone to "stay at home" [8]. Given the unknown and unexpected aspect of this epidemic in
66 modern times, there is inescapably a lack of research on its psychosocial effects [9].

67 Several remedies have been proposed over time to try to eradicate this virus, or limit its spread. The most famous
68 examples are Chloroquine (CQ) and Hydroxychloroquine (HCQ) with or without Azithromycin, still used today as
69 the last alternative in some countries [10-12]. Other notable examples of proposed remedies include Remdesivir
70 [13,14], Favipiravir [15], Dexamethasone [16], Artemesnin [17] and Ivermectin [18]. Actually, as many clinical trials are
71 still repurposing existing drugs [19]. Since the publication of the genetic sequence of SARS-CoV-2, the whole world
72 has actively started trying to produce vaccines [20,21]. At present, out of a total of 8,65 billion administrated doses,
73 more than 3,63 billion people are already fully vaccinated, representing more than 46.6% of the world population [22].
74 Each of the vaccines administered worldwide, actually has been subject to specific studies: Johnson & Johnson [23,24],
75 Pfizer/BioNTech [25,26], Moderna [27,28], AstraZeneca [29,30], and Sputnik V [31,32]. China has around fifteen vac-
76 cines. In addition to being the first developed, they are the most numerous ones [33,34]. The most famous are CanSino
77 [35], Sinopharm [36], and finally Sinovac [37]. The latter, in particular, was subject to very complete studies; the first
78 one demonstrated that this vaccine effectively prevented the virus, including severe disease and death [38]. The se-
79 cond one compared the effectiveness of this vaccine to Alpha and Delta variants, and demonstrated only a meager
80 difference in vaccination effectiveness with the Delta variant compared with the Alpha variant after the receipt of two
81 vaccine doses [39]. The third one showed low efficacy against the omicron variant [40]. The possibility of mixing sev-
82 eral vaccines is also being considered [41]. Currently, the possibility of a fourth dose is considered in some countries
83 especially since the appearance of the Omicron variant [42].

84 Understanding the innate and lifestyle-related factors on the incidence and severity of COVID-19 is critical for making
85 appropriate recommendations to prevent the transmission of COVID-19 as well as the development of severe
86 COVID-19. However, the detailed characteristics influencing the rate and severity of COVID-19 is not fully under-
87 stood. Previously, the published studies were mainly interested in the influence of COVID-19 on the changes of life-
88 style and not the opposite [43,44]. So far, the COVID-19 questionnaires related much more to the perception of people
89 concerning this epidemic [45]. Since the epidemic had occurred, several international questionnaires were created.
90 Their purpose was to answer specific question, e.g., about the knowledge and attitude of residents in the prevention
91 and control of COVID-19 [2], or the preventive practices against COVID-19 pandemic in the general population [46].
92 They were about the mental health impact on people with and without depressive, anxiety, or obsessive-compulsive
93 disorders [47], eating habits, activity and sleep behavior [48], etc. Others focused on particular countries like China
94 [49], USA [50], and France [51]. Herein, we conducted a cross-sectional analysis to evaluate the influence of innate and
95 lifestyle characteristics on COVID-19 by using an online questionnaire based on the literature review as follows.

96

97 1.2. Literature review on the main risk factors

98 A comprehensive literature review using databases and search engines, such as the Web of Science, Google Scholar,
99 PubMed, and Scopus, was carried out to acquire a global overview of the relationships between the different risk fac-

tors and COVID-19. The following keywords: "coronavirus", "COVID-19", "questionnaire", "survey", "tobacco", "alcohol", "lifestyle", "behavior", "immunity", "ethnic origin", "continent", "country", "epidemic", "blood group", "sports activity", "age", "educational attainment" and "preventive measures" were included in our search. The search yielded more than 201 related articles. Furthermore, after screening the titles, abstracts, and full contents, approximately 170 articles were found relevant. 64 were used in the literature review.

The literature review allowed for identifying the risk factors described in the introduction. The conclusion of several studies has amply demonstrated that changes in individual factors would directly (or indirectly) affect the spread of virus. Through literature review and expert opinion, some factors were found to be determinant, e.g. age, social distancing, air temperature, ventilation/airflow, humidity, population density, and community consciousness. These factors were interdependently found to have a strong impact on the SARS-CoV-2 epidemic characteristics [52,53].

110

111

1.2.1 Tobacco

According to the WHO, tobacco is one of the main causes of premature death and morbidity. It is known that smoking and consuming smokeless tobacco (SLT) products significantly increases the risk of NCDs (non-communicable diseases). According to Islam and Walton [54], only few studies had investigated the relationship between tobacco consumption and COVID-19 [55]. Some of them have showed that the hospitalization rate of smokers is higher than that of non-smokers [56,57]. Berlin et al. [58] encouraged stopping smoking and repeated gestures that facilitate contamination, and called for the awareness of health authorities. Mistry et al. [59], in their study, found an increased risk of mortality specifically for people over 65, especially those who live in urban areas, because they are exposed to pollution. Yingst et al. [55] stated that that the increased stress can be detrimental, and it is imperative to create innovative methods to support users interested in quitting during this particularly difficult period.

1.2.2 Alcohol

Alcohol consumption increases the risk of community-acquired infections [60]. Nonetheless, news and media showed that the false propaganda of racketeers misled the public into believing that, since alcohol can remove viruses, its consumption can destroy the coronaviruses after entering the body, supposedly because ethanol is commonly used for hand sanitizers [61], but inescapably this is nothing more than a myth. Some studies demonstrated that alcohol poisoning, which is a consequence of the increase in alcohol consumption, increased significantly especially with the appearance of SARS-CoV-2 epidemic [62,63]. In most communities, alcohol poisoning is responsible for several health issues although it can easily be avoided [64]. The availability of methanol and ethanol in recent years led to an augmentation of morbidity and mortality due to alcohol poisoning in some low-income countries, specifically the Muslim ones [65]. Lassen et al. [66] demonstrated that weekly alcohol consumption is associated with the progression to ARDS during hospitalization with COVID-19, but there is a huge lack of studies dealing with alcohol consumption and infection by SARS-CoV-2.

1.2.3 Physical activity

Regular sports activity is associated with a decrease of 6.0% to 9.0% of the risk of influenza-associated mortality [67]. It was demonstrated previously, through a study on mice that exercise (moderately) in the first days after an influenza virus infection, that the mortality was reduced [68]. However, it remains unclear how the physical exercise affects infections. Endurance exercise that lasts less than 1 hour stimulates NK cell cytotoxicity [69]. Moreover, mild physical activity may boost the immune system, whilst exhausting exercise may weaken it [70]. In general, an unhealthy lifestyle could have negative consequences, whether dealing with the virus now or in the post-COVID-19 period, specifically in sedentary people. The consequences that a sedentary situation can cause and which we can observe over time are, inexorably, cardiovascular diseases, like obesity, diabetes, hypertension, and metabolic syndrome, because a decrease in activity is logically associated with a reduction in insulin sensitivity according to Narici et al. [71]. The same authors claimed that inactivity during confinement could result in a reduction of cardiac volume, oxygen absorption capacity, and VO₂max (maximum oxygen consumption). A reduction in VO₂max and the absorption capacity of oxygen (O₂) is often associated with a high mortality rate. In addition, this decrease affects blood circulation and the oxidative function of muscles. In these circumstances, sports activity can be defined as a key strategy to fight against unhealthy lifestyle during the pandemic or even after [72] since it contributes to maintaining an optimal state of health (mental/physical). The WHO proposed many general recommendations for sports activity to combat the confinement situation. It consists of performing 150 min or at least 75 min/week of physical activity (moderate or vigorous). It is also recommended to combine activities of different intensities [73].

1.2.4 Blood group

152

153 The majority of studies reported that group A had an increased frequency amongst SARS-CoV-2 infection risk, and
154 the opposite for group O, which is associated with a decreased frequency and risk of infection [3,74]. However, recent
155 studies have shown neither an association between blood group and COVID-19 infection susceptibility nor between
156 blood group O and a decreased risk of infection [75]. The role of blood group in the infectivity of SARS-CoV-2 and
157 COVID-19 severity requires further studies. The role of ABO type is likely secondary and non-modifiable [76] and,
158 apart from blood groups, other population-dependent antigens distribution may be of importance in the fairly hetero-
159 geneous spread of the virus in all the geographic areas [77].

160 1.2.5 Ethnicity

161 Ethnicity is a complex concept, which can include several multiple dimensions, as it is socially constructed and may
162 be associated with biological attributes, such as skin color [78]. Black, Asian, and minority ethnic communities in the
163 UK made up 36.0% of the critically ill patients with COVID-19 requiring intensive care [79]. This phenomenon is not
164 specific to UK; it turns out that this is usually the case in several countries. There is considerable evidence that the
165 incidence of clinically important diseases is higher in many minority ethnic groups despite the fact that impacts of
166 race/ethnicity are likely to vary in different countries, as underlined by some studies [80,81].

167 Some meta-analyses were published recently. According to Sze et al. [82], there is a clear confirmation that patients of
168 Asian, Black, and Hispanic ethnicities have an increased probability of being infected with coronavirus, compared to
169 white ethnics. In addition, there is a possibly higher risk of intensive care admission and death in Asians. Their find-
170 ings should be used by institutions and decision-makers to minimize the exposure to COVID-19 in ethnic minorities.
171 This can be achieved through some measures such as helping them access health care resources quickly, observing
172 ethical standards and eliminating as much as possible all forms of racism, social determinism, and inequalities. For
173 Vist et al. [83], even if there is an increased risk of infection and hospital admission due to SARS-CoV-2 for several
174 immigrants and minority ethnic groups, this is especially associated with a low socioeconomic status, resulting into
175 higher admission to hospital and death rates compared to groups with a high socioeconomic status. The fact that may
176 explain the tragic situation in some countries compared to others with almost similar ethnicity [84].

177 1.2.6 Gender

178 Generally, data around the world indicate higher COVID-19 case fatality rates among men than women [85]. Gen-
179 der-based behavioral and socio-cultural differences may contribute to the sex differences reported in the severity of
180 COVID-19 disease. For example, men wash their hands lesser, especially with soap or other products after entering a
181 restroom, and are more likely to smoke [86].

182 A large-scale data of two meta-analysis studies demonstrated that despite the fact that there are no significant differ-
183 ences in the proportion of infected individuals with the virus, men are much more likely to develop serious illnesses
184 and die compared to women [87,88] except for some countries like India [89]. According to Bhopal and Bhopal [90],
185 hypotheses based on risk factors that are known to change with both sex and age seem to be the most probable expla-
186 nations for the observed differences. The differences are due to lifestyle (e.g., alcohol, smoking), occupation, use of
187 medications, or medical co-morbidities. These descriptions reflect cultural and social characteristics associated with
188 gender rather than the biology of sex.

189 1.2.7 Age

190 Since the beginning of the epidemic, age has been defined as the keystone in COVID-19 infected people [91]. The first
191 data coming from Italy also attested that mortality was highly significant in septuagenarian patients and even higher
192 in octogenarians [92]. A meta-analysis has suggested an essential influence of age on mortality of infected patients
193 with a relevant threshold on age>50 and more especially>60 [93]. This epidemic reminds us daily that older individ-
194 uals, specifically those with rheumatic diseases [94], are extremely vulnerable to infectious diseases due to
195 co-morbidities linked with age and a decrease in immunological competence or “immunosenescence” [95]. This pro-
196 cess, particularly the increased production of inflammatory cytokines resulting from inflammation, is partly responsi-
197 ble for determining the prognosis of COVID-19 in elderly individuals. [96].

198 The peculiarities of the immune system of older individuals may contribute to both the deficiency of effector mecha-
199 nisms essential for viral pathogens fighting and an exacerbated inflammatory response, which can accelerate and in-
200 tensify lung tissue damage [97]. Nonetheless, several authors agree on the fact that one should in no way consider
201 COVID-19 as a “disease of the elderly”, but the pandemic should be considered as a temporary setback in a long-term
202 decline in senescent mortality [98].

203 1.2.8 Resistance (immunity)

204 The genetic background of patients and presence of concomitant pathological conditions were also examined, pro-
205 vided that adaptive immunity to closely related viruses or other microorganisms can reduce susceptibility or increase

206 the severity of disease [99]. In line with some studies, seemingly most severely affected people have misguided anti-
207 bodies (autoantibodies) that attack the immune system rather than the virus that causes the disease. A small percent-
208 age of the population who develop severe COVID-19 is characterized by a specific genetic mutation that affects im-
209 munity. Consequently, many individuals lack effective immune responses, which depend on type I interferon
210 [100,101].

211 At the same time, it seems that a part of population is more resistant to COVID-19, for example, according to the
212 study by Le Bert et al. [102], some have developed immune cells called T lymphocytes, which are directed against the
213 new coronavirus. This immune response would be "lasting", unlike antibodies, which would disappear quickly.
214 Above all, this response would be present in more than 50.0% of healthy people who have never been infected with
215 the coronavirus. It also demonstrated that different efficacy of both innate and immune responses, according to age
216 and co-morbid conditions, can be a confounding factor [103]. Grasping the combinational and individual role of hosts,
217 environmental factors, and viral ones in COVID-19 infection provides a better knowledge of the eventual high-risk
218 groups of people concerning SARS-CoV-2 specifically in terms of severity and susceptibility [104].

219 1.2.9 Educational attainment

220 It has been demonstrated that educational level has an effect on the incidence of some diseases (specifically
221 non-communicable). Low levels of education are related to high prevalence and incidence of cerebrovascular and
222 cardiovascular diseases, cancer, diabetes, hypertension, and chronic respiratory diseases [105]. Generally, a bad soci-
223 oeconomic status may be linked to low educational level, thus increasing the risk of previously mentioned diseases
224 [106], and of COVID-19 because of low levels of immune cells and high levels of Cytokines in body fluids [107]. It
225 should be remembered that the access to education is not the same elsewhere; when examining urban versus rural
226 outcomes in COVID-19, the disparities are markedly evident when considering county-level data [108]. Concerning
227 the relationship between COVID-19 and educational level, it is acknowledged that education and engagement in
228 health behaviors are positively associated [109], and low education is associated with unhealthy behaviors [110].
229 However, several external factors may be examined and additional measures will have to be studied each time to test
230 for this relationship [111]. Some studies have also suggested that a standardized measurement should be used in fu-
231 ture studies [112].

232 1.2.10 The continent of residence

233 As a pandemic, COVID-19 had hit almost every country on earth. Different approaches to emergency management
234 were adopted in each country [113] as in East Asia [114]. Some studies analyzed the differences and similarities in
235 how the inhabitants of different countries responded to government policies enacted during the spread of the
236 COVID-19 pandemic [115] by measuring for example confirmed cases and deaths, the stringency index. The results
237 varied according to each country [116]. If possible, a more government-related response would be worth investigat-
238 ing. Nevertheless, it has been demonstrated that the lag time in responding to government policy and response varia-
239 bility in each country are significantly correlated with the numbers of infections and deaths [117].

240 1.2.11 Observance of protective measures

241 According to the WHO [6], there are many health precautions that individuals can take to avoid COVID-19 infection
242 including frequent hand-washing, wearing facial coverings, maintaining a 2 m distance between themselves and oth-
243 ers, staying away from crowds, coughing/sneezing into the elbow (or mask), cleaning/disinfecting surfaces regularly,
244 and examination by a doctor if necessary as recommended by the CDC [118]. In addition, we included vaccination
245 among the strict preventive measures given that at the time when the questionnaire was created, the vaccination pro-
246 cess was barely starting and its contribution almost negligible. However, we still have considered it as an additional
247 measure, and discussed in more detail in the introduction.

248

249 1.3. Aims and importance of research

250 Given the ambiguity of answers from previous studies that used questionnaires, the present research was designed
251 to correct some past limitations. The aim of this study was to investigate the effects of factors beyond human control
252 (e.g., blood group, ethnicity) on COVID-19 potential infection and severity, and of lifestyle or behavioral characteris-
253 tics (e.g., tobacco use, sports activity, and alcohol consumption). Based on the fact that the number of infections varies
254 greatly by country and continent (even if this may also be due to significant variations in the level of underreporting
255 of cases between countries), we hypothesized that the innate factors should be the most significant in deciding on the
256 possible infection of individuals. We examined this assumption using questionnaires for quantification.

257 2. Materials and Methods

258 2.1 Overview

259 The present study is based on a cross-sectional design, using an online questionnaire. The main function of question-
260 naires was to give the survey a greater extension. It was also used as a means to verify statistically the extent of gener-
261 alization that can be reached by the existent information and preliminary assumptions [119].

262 To accomplish the aim, we designed an anonymous online survey with a sufficient number of items; its qualities in-
263 clude conciseness, scientific structure, pre-testing and global practicability. Considering the lack of similar works, the
264 questionnaire addressed some basic information and all major lifestyle aspects. To ensure optimal compliance with
265 preventive measures against the spread of virus, we have deliberately chosen to share the survey exclusively online,
266 to limit contact as much as possible. A standardized methodology including steps such as literature review, expert
267 review, ethical approval and pre-testing were undertaken to develop and validate the questionnaire [120,121].

268

269 2.2 Development of the questionnaire

270 We drafted our questionnaire in four languages: Arabic, English, Spanish and French, which are in the top 6 most
271 spoken worldwide, along with Chinese and Hindi [122]. The data was collected via Google Forms, through a
272 self-report questionnaire. Additionally, the questionnaire consisted of three main parts. The first one was related to
273 the socio-demographic characteristics. The second part consisted of items related to behavior, and the last part in-
274 cluded the infection status (yes or no) and its severity. We made the questionnaire as easy as possible with a mini-
275 mum of items, so that it could be understood by almost the entire world population. We have particularly made sure
276 that it is very fast to answer so as not to be discouraging, while deliberately excluding criteria that are too subjective
277 or difficult to measure (e.g., hours of sleep, quality of nutrition, and stress rate). To highlight the importance of re-
278 search and great credibility, the tool was presented to a committee of national and international experts who helped to
279 improve it by deleting or rewording some items. Their intervention made possible to ensure its suitability and validity
280 before applying it to the participants. Conventionally, the ethical approval and consent were obtained from the
281 CRSTRA and all participants. The questionnaire was shared via social media including Instagram, Facebook,
282 LinkedIn, WhatsApp and volunteer participants were requested to fill in the online form. However, we required that
283 the respondents should be at least 18 years old to answer, and asked for a confirmation for each respondent.

284

285 2.3. Statistical analysis

286 Statistical analyses were performed using SAS® (version 9.4). We coded the contamination factors on a numerical
287 scale due to their nature (nominal or ordinal variable). For this reason, the responses were coded as following:

288

289 A progressive scale describing the direction of variation concerning the factors of an ordinal nature:

290 -Educational attainment: 0-3 (0=Not precise, 1= No study or primary, 2= Middle/secondary, 3= Universi-
291 ty/post-university) - Age: 1-4 (1=18-30, 2= 31-45, 3= 46-59, 4= 60+) - Sports activity: 1-3 (1= Little or no activity, 2= Mod-
292 erate, 3= Very active) - Health status: 1-3 (1=Resistant, 2= Moderately sensitive, 3= Very sensitive). - Tobacco use: 1-3
293 (1=No, 2= Occasionally, 3= Frequently) - Alcohol consumption: 1-3 (1=No, 2= Occasionally, 3= Frequently) - Protective
294 measures against COVID-19: 1-3 (1=Not at all, 2= Medium application, 3= Strict application) - Severity: 0-3 (0=Healthy,
295 1= Low, 2= Treatment, 3= Intensive care).

296 A two-choice scale for the question: "Have you been affected by COVID-19?" (No=0, Yes=1).

297 A random scale for factors of a nominal nature: - Residence (1=Africa, 2= Europe, 3= North America, 4= South Ameri-
298 ca, 5= Asia, 6= Oceania) - Ethnicity (0= Not precise, 1= Other, 2=African / Afro-American, 3= Caucasian, 4= Arabic, 5=
299 Asian, 6= Latino) - Gender (0=Not precise, 1= Male, 2= Female, 3= Other).

300 We noticed that the estimations of odds ratios were affected by very small sample size for specific levels of the varia-
301 bles. In order to increase the validity of statistical analyses, data for some levels were removed, by changing them to
302 missing observations: Gender – 3 "Other" values, Continent – 2 "Oceania" values, Health – 1 "0=Healthy" value, Con-
303 tinent – 10 "4=South America" values, and Ethnicity – 11 "6=Latino" values. However, we did not eliminate any blood
304 groups, despite of the reduced sample size influencing in one case the estimation of odds ratios, because it make no
305 sense from a health standpoint.

306 Two statistical analyses were run:

- 307 • The dependence of having been affected before or not by COVID-19 on the potential risk factors investigated
308 was analyzed using logistic regression, a statistical method modeling a binary event as probability of its occurrence.

309 • The dependence of the severity of infection on potential risk factors investigated was also analyzed using lo-
 310 gistic regression, after eliminating healthy subjects from the analysis and turning the “Severity” variable into a binary
 311 one, which indicates if the patient needs treatment or intensive care.

312 Provided that the difference in the odds ratios is not the same for the different levels of the predictors considered in
 313 this study, absolutely all independent variables were treated as categorical in all analyses.


314 Model selection was performed with the intention of finding a model including only predictors with a significant
 315 impact on the response when acting together. The model selection was performed using the approach proposed by
 316 Collett [123], consisting of: (1) performing univariate regressions with each predictor separately, (2) building a first
 317 multivariable model with all predictors if their p-values in (1) were below 0.2; (3) performing a backward elimination
 318 with the model obtained in (2), by eliminating the variable with the least influence on the response (indicated by the
 319 highest p value), until all variables in the model had a statistically significant influence on the response, and (4) at-
 320 tempting to re-include variables not retained at the end of (3), in order to check if the model quality can be improved.

321 For all statistical analysis, the level of significance was 0.05. However, since the sample size was not very large, the
 322 presentation of results also includes results significant at the 0.1 level. In this case, additional data would probably
 323 have led to significant results.

324 3. Results

325 3.1. Descriptive statistics

326 For a total of 1125 responses, 753 responses (67.0%) were made in French, 225 (20.0%) in Arabic, 135 (12.0%) in Eng-
 327 lish, and finally 12 (1.0%) in Spanish.



328
 329 **Figure 1.** Representation of received answers

330 For 1125 respondents, 332 were COVID-19 positive, 130 required home-based treatment, and 14 required an intensive
 331 care.

332 **Table 1.** Characteristics of the sample study

Characteristics	Answers	Sample	Percentage %
Continent of residence	Africa	963	85.6%
	Europe	83	7.4%
	North America	19	1.7%
	South America	10	0.9%
	Asia	48	4.3%
	Oceania	2	0.2%

	Not precise	13	1.2%
	Other	98	8.7%
Ethnic origin	African / Afro-American	126	11.2%
	Caucasian	61	5.4%
	Arabic	794	70.6%
	Asian	22	2.0%
	Latino	11	1.0%
	not precise	7	0.6%
	Gender	Male	394
Female		721	64.1%
Other		3	0.3%
Age	18-30 years	727	64.6%
	31-45	315	28.0%
	46-59	60	5.3%
	60	23	2.0%
	not precise	13	1.2%
Blood group	A+	344	30.6%
	A-	21	1.9%
	B+	163	14.5%
	B-	17	1.5%
	AB+	56	5.0%
	AB-	8	0.7%
	O+	471	41.9%
	O-	32	2.8%
	Not precise	0	0.0%
Educational attainment	No study or primary	67	6.0%
	Middle or secondary	236	21.0%
	University or post-university	820	73.0%
	Little or no activity	557	49.6%
Sports activity	Moderate	451	40.2%
	Very active	114	10.2%
Health status	Resistant (little or no flu / colds...)	730	65.3%
	Moderately sensitive (regularly subject to flu / colds...)	331	29.6%
	Very sensitive (suffering from chronic disease (s) or others)	57	5.1%
Tobacco use	No	962	85.7%
	Occasionally	83	7.4%
	Frequently	78	6.9%
Alcohol Consumption	No	1025	91.4%
	Occasionally	81	7.2%
	Frequently	16	1.4%
	Not at all	65	5.8%
Observance of protective measures	Medium application	649	57.7%
	Strict application	411	36.5%

Infection with COVID-19	No	790	70.4%
	Yes	332	29.6%
	Healthy (no infection)	802	71.3%
Infection state	Low (no special care)	179	15.9%
	Treatment and /or care	130	11.6%
	Intensive care	14	1.2%

333

334 3.2. Data analysis

335 Table 2 presents an overall image of analyses looking at the influence of considered predictors on the infection with
336 COVID-19 and its severity. For each of the two, the table displays three models in separate columns. The first one
337 looks at the individual relationship between the infection with COVID-19 and its severity with each predictor. The
338 second column presents a “full model”, ascertaining the simultaneous influence of all predictors on the infection with
339 COVID-19 and its severity. Finally, the third column presents a “prediction model”, resulted from the full one, and
340 containing only predictors with a significant influence on the infection with COVID-19 and its severity, when consid-
341 ered simultaneously. The table clearly shows that age, sports and health status were significantly associated with the
342 infection with COVID-19, whereas tobacco and protection were significantly associated with its severity.

343 **Table 2.** Analysis of the influence of considered predictors on the infection with COVID-19 and its severity. The table describes the
344 influence, separately (column labeled “Univariate”), the simultaneously (column labeled “Full model”) and a final model resulting
345 from selection including only predictors with a statistically significant simultaneous influence (column labeled “Selected model”).
346 **Bold** values indicate a statistically significant impact ($p \leq 0.05$), and those in *Italic* a marginally significant impact ($0.05 < p \leq 0.1$).

Influence (Model)	Dependent variable					
	Infection			Severity		
	Univariate	Full model	Selected model	Univariate	Full model	Selected model
Continent	0.3949	<i>0.0891</i>		0.2074	<i>0.0888</i>	
Ethnicity	0.3217	0.1553		0.9307	0.6429	
Gender	0.1654	0.7951		0.1088	0.7922	
Age	0.0027	0.0185	0.0019	0.4958	0.6296	
Blood	<i>0.0667</i>	0.1869		0.4963	0.4590	
Education	0.2661	0.5919		0.6485	0.6156	
Sports	0.0009	0.0010	0.0005	0.1478	0.2808	
Health	0.0032	<i>0.0919</i>	0.0118	<i>0.0723</i>	0.1300	
Tobacco	<i>0.0934</i>	0.6743		0.0164	0.3364	0.0370
Alcohol	0.1483	0.7615		0.1589	0.3068	
Protection	0.4519	0.4083		0.0004	0.0042	0.0015

347 Having been affected or not by COVID-19 was analyzed via logistic regression whose results are presented in Table 3.
348 The model was overall significant ($p < 0.0001$). The logistic regression demonstrated that age, sports activity and
349 health status showed significant impacts on the infection of COVID-19.

350 **Table 3.** Results of the logistic regression showing the factors determining whether a subject has been affected by COVID-19 or not.
 351 **Bold** values indicate a statistically significant impact ($p \leq 0.05$), and those in *Italic* a marginally significant impact ($0.05 < p \leq 0.1$). The
 352 model includes all analyzed factors.

Variable	DF	Wald Chi-Square	p-value	Level	OR Estimate	95% Lower Wald Confidence Limit	95% Upper Wald Confidence Limit
<i>Continent</i>	3	6.5147	0.0891	<i>Africa vs. North America</i>	0.355	0.013	9.687
				<i>Asia vs. North America</i>	0.691	0.014	34.708
				<i>Europe vs. North America</i>	2.781	0.083	92.650
				Other vs. Asian African / Afro-American vs. Other	2.790	0.222	35.031
Ethnicity	4	6.6549	0.1553	Caucasian vs. Asian	2.198	0.154	31.419
				Arabic vs. Asian	9.962	0.571	173.918
Gender	1	0.0674	0.7951	Male vs. Female	4.956	0.369	66.604
Age	3	10.0082	0.0185	18-30 vs. 60+	1.089	0.571	2.076
				31-45 vs. 60+	13.133	1.238	139.335
				46-59 vs. 60+	4.112	0.413	40.952
Blood	7	10.0299	0.1869	A+ vs. O-	3.485	0.293	41.460
				A- vs. O-	3.081	0.638	14.887
				B+ vs. O-	<0.001*	<0.001*	>999.999*
				B- vs. O-	1.192	0.224	6.338
				AB+ vs. O-	4.288	0.125	147.175
				AB- vs. O-	9.939	1.106	89.323
				O+ vs. O-	0.474	0.010	22.533
Education	2	1.0488	0.5919	No study or primary vs. University/ post-university	2.720	0.569	12.987
				Middle/ secondary vs. University/ post-university	1.401	0.514	3.820
				Little or no activity vs. Very active	1.535	0.597	3.947
Sports	2	13.7657	0.0010	Moderate vs. Very active	2.729	0.978	7.620
Health	2	4.7731	0.0919	Resistant vs. Very	0.941	0.346	2.559
					4.078	1.069	15.559

Variable	DF	Wald Chi-Square	p-value	Level	OR Estimate	95% Lower Wald Confidence Limit	95% Upper Wald Confidence Limit
				<i>sensitive</i>			
				<i>Moderately sensitive vs. Very sensitive</i>	3.007	0.769	11.763
Tobacco	2	0.7881	0.6743	No vs. Frequently	0.647	0.191	2.189
				Occasionally vs. Frequently	0.531	0.131	2.155
Alcohol	2	0.5448	0.7615	No vs. Frequently	0.683	0.077	6.035
				Occasionally vs. Frequently	0.460	0.041	5.129
Protection	2	1.7915	0.4083	Not at all vs. Strict application	1.629	0.546	4.859
				Medium application vs. Strict application	1.462	0.815	2.622

353 * The estimates are unusually large, because in reality they exceed the program thresholds. This happens because of the very low
354 sample size for specific levels (groups). While some were eliminated from the analysis (e.g., Gender – 3 “Other” values, Continent –
355 2 “Oceania” values, Health – 1 “0=Healthy” value, Continent – 10 “4=South America” values, and Ethnicity – 11 “6=Latino” values),
356 it did not make sense eliminating a blood group, for medical reasons.

357 Since not all factors in Table 3 were found to exert a statistically significant influence on having been affected or not by
358 COVID-19, model selection was run in order to identify a model where all factors significantly affect the probability of
359 having been affected or not by COVID-19. The model resulted by eliminating, in this order, the variables tobacco,
360 gender, education, blood, and ethnicity. The resulting model, significant at $p < 0.05$, is displayed in Table 4.

361 **Table 4.** Results of the logistic regression showing the factors determining in a statistically significant way whether a subject has
362 been affected by COVID-19 or not. All factors have a statistically significant impact ($p \leq 0.05$). Some levels were eliminated from the
363 analysis (e.g., Gender – 3 “Other” values, Continent – 2 “Oceania” values, Health – 1 “0=Healthy” value, Continent – 10 “4=South
364 America” values, and Ethnicity – 11 “6=Latino” values), but it did not make sense eliminating a blood group, for medical reasons.

Variable	DF	Wald Chi-Square	p-value	Level	OR Estimate	95% Lower Wald Confidence Limit	95% Upper Wald Confidence Limit
				18-30 vs. 60+	10.841	1.247	94.234
Age	3	14.8694	0.0019	31-45 vs. 60+	4.707	0.531	41.732
				46-59 vs. 60+	3.940	0.377	41.199
				Little or no activity vs. Very active	2.820	1.192	6.668
Sports	2	15.3573	0.0005	Moderate vs. Very active	1.037	0.448	2.400
Health	3	8.8880	0.0118	Resistant	5.158	1.587	16.763

vs. Very sensitive
Moderately sensitive vs. Very sensitive

3.384 1.010 11.337

365 The dependence of the severity of infection on potential risk factors investigated was analyzed using the logistic re-
366 gression. The results are presented in Table 5. The model was overall significant (p = 0.0201). Here, the respect of pro-
367 tective measures and smoking were significantly associated with the severity of infection.

368 **Table 5.** Results of the logistic regression showing the factors determining whether a subject has been severely affected by
369 COVID-19 or not. Variables with names written in **Bold** have a statistically significant impact, and those in *Italic* a marginally
370 significant impact (0.05<p≤0.1). The model includes all analyzed factors. Some levels were eliminated from the analysis (e.g.,
371 Gender – 3 “Other” values, Continent – 2 “Oceania” values, Health – 1 “0=Healthy” value, Continent – 10 “4=South America”
372 values, and Ethnicity – 11 “6=Latino” values), but it did not make sense eliminating a blood group, for medical reasons.

Variable	DF	Wald Chi-Square	p-value	Level	OR Estimate	95% Lower Wald Confidence Limit	95% Upper Wald Confidence Limit
				<i>Africa vs. North America</i>	0.531	0.156	1.803
Continent	3	6.5229	0.0888	<i>Asia vs. North America</i>	1.339	0.303	5.916
				<i>Europe vs. North America</i>	0.966	0.255	3.654
				Other vs. Asian African / Afro-American	1.873	0.593	5.916
Ethnicity	4	2.5095	0.6429	vs. Other Caucasian vs. Asian	1.568	0.497	4.953
				Arabic vs. Asian	1.167	0.336	4.050
Gender	1	0.0694	0.7922	Male vs. Female	1.756	0.582	5.299
				18-30 vs. 60+	0.957	0.690	1.327
Age	3	1.7330	0.6296	31-45 vs. 60+	1.450	0.539	3.899
				46-59 vs. 60+	1.199	0.455	3.162
				A+ vs. O-	0.986	0.330	2.949
				A- vs. O-	1.465	0.643	3.341
				B+ vs. O-	5.754	1.067	31.035
Blood	7	6.7163	0.4590	B- vs. O-	1.655	0.695	3.944
				AB+ vs. O-	3.469	0.624	19.265
				AB- vs. O-	2.032	0.734	5.626
				O+ vs. O-	1.575	0.241	10.299
				1.422	0.630	3.209	
Education	2	0.9703	0.6156	No study or primary vs. University/	0.946	0.538	1.664

Variable	DF	Wald Chi-Square	p-value	Level	OR Estimate	95% Lower Wald Confidence Limit	95% Upper Wald Confidence Limit
				post-university Middle/secondary vs. University/post-university	1.250	0.767	2.035
Sports	2	2.5403	0.2808	Little or no activity vs. Very active	0.968	0.585	1.603
				Moderate vs. Very active	0.777	0.470	1.283
Health	2	4.0803	0.1300	Resistant vs. Very sensitive	1.273	0.691	2.345
				Moderately sensitive vs. Very sensitive	0.943	0.502	1.772
Tobacco	2	2.1788	0.3364	No vs. Frequently	0.985	0.550	1.765
				Occasionally vs. Frequently	0.673	0.331	1.368
Alcohol	2	2.3629	0.3068	No vs. Frequently	1.864	0.550	6.324
				Occasionally vs. Frequently	1.243	0.334	4.631
Protection	2	10.9263	0.0042	Not at all vs. Strict application	0.387	0.210	0.715
				Medium application vs. Strict application	0.700	0.517	0.947

373 Since not all factors in Table 5 were found to exert a statistically significant influence on the severity of COVID-19
374 infection, model selection was run in order to identify a model where all factors had a significant influence. The model
375 resulted by eliminating, in this order, the variables gender, education, ethnicity, tobacco, blood, sports, continent, and
376 age. The resulting model, significant at $p < 0.05$, is displayed in Table 6.

377 **Table 6.** Results of the logistic regression showing the factors determining in a statistically significant whether a subject has been
 378 severely affected by COVID-19 or not. All factors have a statistically significant impact ($p \leq 0.05$). Some levels were eliminated from
 379 the analysis (e.g., Gender – 3 “Other” values, Continent – 2 “Oceania” values, Health – 1 “0=Healthy” value, Continent – 10
 380 “4=South America” values, and Ethnicity – 11 “6=Latino” values), but it did not make sense eliminating a blood group, for medical
 381 reasons.

Variable	DF	Wald Chi-Square	p-value	Level	OR Estimate	95% Lower Wald Confidence Limit	95% Upper Wald Confidence Limit
Tobacco	2	6.5963	0.0370	No vs. Frequently	0.983	0.589	1.641
				Occasionally vs. Frequently	0.539	0.280	1.040
				Not at all vs. Strict application	0.382	0.220	0.663
Protection	2	13.0085	0.0015	Medium application vs. Strict application	0.725	0.547	0.961

382 4. Discussion

383 4.1 Significance of the results and health recommendations

384 In this cross-sectional study, we evaluated association between innate and lifestyle-related factors on the rate and
 385 severity of COVID-19. The main findings are as follows: 1) age, physical activity, and health status were found to have
 386 a significant influence on the infection of COVID-19; 2) observance of preventive measures and tobacco consumption
 387 had a significant influence on the severity of the infection of COVID-19.

388 We confirmed the significant influence of the following factors on the possibility of infection: age, sports activity and
 389 to a lesser degree health status. We could thus interpret the factors on the rate of infection is by the fact that the older
 390 the person is, the more the individual will be subject to the infection, and this is confirmed with the positive wideness
 391 of the estimated parameter of the logistic regression, thus agreeing with previous studies [93,95]. With regard to
 392 physical activity, our results showed that the more active the individual, the less likely he is to be infected with the
 393 virus, this was also confirmed by the positive wideness of the estimated parameter of the logistic regression and
 394 agreeing with the previous studies [71,73]. While for the health status, the estimated parameter indicates that the more
 395 the individual's sensitivity increases, the more the individual will be subject to infection, only confirming the results of
 396 previous studies concerning immunity [102]. Our results indicate that the compliance with preventive measures is
 397 essential. It seemed obvious to remind each time to observe the protective measures (wearing the mask, quarantine,
 398 remote working, hygiene, vaccination, etc.). The problem is that the average population thinks that after being vac-
 399 cinated it is no longer mandatory to apply preventive measures [124]. It is true that previous studies have shown that
 400 vaccination of health care workers was associated with a substantial reduction in infections [125] or that one dose of
 401 vaccine reduces the potential for transmission by 61.0% [126], but the contamination possibility still exists. We en-
 402 courage media and public health organizations to clarify this information [127].

403
 404 In the same vein as for the probability of infection, it would seem for the severity that the more an individual smokes,
 405 the more severe his infection will be and will in most cases lead to hospitalization thus confirming the logic of previ-
 406 ous work [56,57]. With regards to protective measures, the logistic regression showed that the more the individual was
 407 strict in his application of the preventive measures promoted by the WHO and CDC [118], the less likely he will have
 408 a severe infection if he was infected. A previous online questionnaire observational study demonstrated that the use
 409 of protective measures was not associated with symptom severity of COVID-19 [128]. Another South Korean study
 410 showed that preventive measures had a negative influence on cardio metabolic profiles in subjects with metabolic
 411 impairments [129]. To our knowledge, there has not been any work that has demonstrated the positive effect of pre-
 412 ventive measures on COVID-19. In contrast, a study in Pakistan showed that the application of protective measures
 413 dramatically reduces the risk of other respiratory diseases [130] Recently a Japanese study focused only on wearing a
 414 mask as a measure and they found that for a sample of 820 individuals, mask users were infected at a rate of 0.4 times

415 that of those who did not wear masks [131] demonstrating the importance of this measure. Our findings provide
416 novel insights into the role of personal protective measures on the spread of infection and symptom severity. Further
417 study is warranted to confirm our findings.

418 Regarding age, since the beginning this pandemic, COVID-19 has always been associated with old individuals [132].
419 A higher need for intensive care increase by age among individuals older than 45 years [133]. Our findings only con-
420 firm the importance of this factor by going in the same direction as previous reviews and meta-analysis studies
421 [134,135].

422 Concerning alcohol, the situation is a little paradoxical. Our findings showed that the alcohol consumption has no
423 significant influence on the probability of infection and its severity. However, Abbasi-Oshaghi et al. [136] found the
424 opposite, because long-term drinking is closely related to zinc and vitamin deficiency. Hikida et al. [137] also found
425 out that alcohol probably increases the risk of exposure to and morbidity from COVID-19. In addition, according to
426 the same study, alcohol consumption is associated with prosecution and having regrets, which can increase the sever-
427 ity of COVID-19. González-Reimers et al. [138] discussed the fact that it has already been proven that various chronic
428 disorders may increase the risk of pneumonia (and by extrapolation COVID-19) severity. Precisely for the severity, a
429 Chinese study performed on more than 1,500 patients claimed that the severity of infection was greater in patients
430 who consume alcohol regularly or with a history of consumption [139]. At the same time, a recent review article also
431 confirmed that alcohol consumption adds vulnerability to patients and leads to an increased severity of COVID-19
432 and other long-term health problems [140]. Nevertheless, others remain a little less categorical leaving doubt by
433 pointing out the influence of several factors at the same time as well as the need for further studies [141,142].

434 While for tobacco, the results of our work are quite logical because it was more associated with the severity of infec-
435 tion compared to the infection. Indeed, non-smokers are obviously not immune to the virus; however, smoking pa-
436 tients are vulnerable to severe COVID-19 [143]. This perfectly confirms the findings of previous studies [144,145].

437 In general, the measures must be subject to a special focus especially for sensitive sectors. Citing as an example the
438 education sector, where the application of measures was investigated in a few articles [146,147] but the most striking
439 example remains, as stated previously, the health sector [148,149]. We think that it is important for each individual to
440 educate about his own health on a regular basis. This issue remains debatable, as in many countries the relationship
441 between educational disparities and socioeconomic status is discussed a lot without reaching a final answer [150,151].
442 Variability in immune system components (innate) is a major contributor to the heterogeneous disease courses noticed
443 for Sars-CoV-2 [152]. The immune response differs from a person to another and should not be relied on in any way
444 provided the still unknown character of several mechanisms [153]. A continuous effort to understand all mechanisms,
445 especially those concerning host-virus interactions, is essential to overcome the pandemic [154]. In our study, a health
446 state was associated with a reduced probability of contracting the virus, which can demonstrate the importance of
447 innate immunity, but in no case should we be totally based on this. Nevertheless, we cannot limit human health solely
448 to these factors, and the effectiveness of vaccine plays the most important role. Further studies are needed to confirm
449 the relationship between vaccines, pollution, and their consequences [155].

450 A point not to be overlooked concerns the sources of information (or disinformation). A recent study on Jordanian
451 and Iraqi participants revealed that more than half of the population of the two countries use social media as the most
452 common COVID-19 information source, sharing a lot of false information which may lead to gaps in the actions to be
453 adopted [156]. A cross-sectional study conducted in Saudi Arabia focused on testing the knowledge of residents with
454 questions about the measures to be taken, and more than 90.0% of the population was above average by specifying in
455 particular that people with a low level of education have failed [157]. Still in the same country, the observance of pre-
456 cautionary measures among nursing staff was studied, and results show that a high number (71.2%) were competent
457 and less qualified personnel should nevertheless be trained in particular [158]. This would be applicable to all coun-
458 tries, and could prove useful.

459 Finally, our original research goal was to analyze the influence of two groups of factors and their influence on
460 COVID-19 to reduce the spread of the virus. These findings also agree with the WHO reports who have constantly
461 repeated the various protective measures to be taken for avoiding any possible infection and thus indirectly limiting
462 the spread of virus [6]. Additionally, this study is one of only few going against the idea that a part of the world pop-
463 ulation is automatically condemned to infection because of their ethnicity, place of residence etc. Our study is meant
464 to be encouraging by showing that each person has almost entirely its destiny in its hands as long as a healthy lifestyle
465 is observe and precautions taken; it is also about advising people to self-educate. This can have only positive effects,
466 even in the long term.

467

468 *4.2 Importance of the study*

469 The originality of this study comes from the fact that it is the only international study providing more information on
470 the African and Mediterranean areas, carried out in 4 different languages. The number of respondents is quite high
471 and heterogeneous compared to almost all questionnaires presented in previous studies. Moreover, the vast majority
472 of publications have focused on a particular sector [159], a particular region [160] or a well-targeted population [161].
473 In addition, previous studies dealt with a single characteristic or group of characteristics [162,163], while the present
474 study includes 13 items based on a substantial literature review. These items addressed two groups of characteristics
475 comparing the most significant ones. Everything was simplified as much as possible in order to reach all categories of
476 the world population and collect more information applicable to the vast majority, so that we can encourage them to
477 adopt the right actions to prevent the infection, and ultimately limit the spread of disease. Moreover, the ranked in-
478 fluence of COVID-19 infection drivers has never been evaluated before. Any additional findings are important, pro-
479 vided their possible contribution to the fight against this pandemic.

480

481 *4.3 Methodological limitations*

482 Our analysis was limited to a number of factors considered as relevant based on the literature review, and which
483 could be ascertained using an online questionnaire. However, different studies also pointed out a number of other
484 potential risk factors.

485 Objectively, it is an almost impossible challenge to know exactly the factors responsible for infection and transmission
486 of COVID-19. Sources may be incomplete; apart from the factors discussed previously, even the meteorological ones
487 were considered a potential explanation [164]. A study in Korea demonstrated that the environment plays a signifi-
488 cant role in the spread of COVID-19, but like any factor, it may have also been impacted by various additional fea-
489 tures [165]. Hence, further studies are needed to protect people from COVID-19 transmission, specifically on infection
490 dynamics and the mode of transmission, e.g., cluster spaces, closed spaces, and indoor environments [166].

491 At the individual level, everyone must take the maximum possible precautions. It should also be remembered that no
492 less than 10 reasons supporting airborne transmission were phrased recently by Greenhalgh et al. [167]. The long-term
493 health consequences of COVID-19 remain unclear and continue to be studied [168]. Therefore, it is preferable to avoid
494 any form of infection, even mild. Another factor that we do not necessarily think about and which may be important
495 is the wastewater treatment and disinfection strategies with chemical products; all demonstrate that we must take into
496 account an incalculable number of factors [169].

497 We can also mention certain biases concerning the sample. The majority of respondents were young intellectuals from
498 the Arab (and Muslim) world; consequently, tobacco and alcohol remain taboo subjects, so it is possible that some
499 respondents did not tell the truth about these characteristics, and our results could be biased. Integrating vaccination
500 as a protective measure rather than as a factor in its own right when carrying out this sampling was not a limiting
501 factor; time has showed that this is the case now.

502

503 *4.4 Perspectives for future research*

504 Undoubtedly, this study could not explicitly pretend to yield results able to stop this pandemic. In general, making
505 predictions on this virus, which remains unknown, is impossible. Therefore, any additional information may prove
506 useful. We consider that each study on this topic contributes in its own way to fighting indirectly against the pan-
507 demic crisis we are currently experiencing. Previously, we have enumerated a certain number of limitations in this
508 work, including the number of answers received to the questionnaire. While this is acceptable, more answers could
509 help obtaining more representative results, and increasing their statistical significance. Future studies should seek to
510 use a larger and even more diverse sample, and include additional recruitment strategies. For example, future studies
511 should include in their sample information provided by parents of children under 18 years old, as they are also a
512 group of high concern given the target specificity of the new virus variants.

513

514 **5. Conclusions**

515 In this study, we found that health status, age and physical activity significantly influence the infection ($p < 0.05$). The
516 non-respect of preventive measures and smoking tobacco significantly aggravate its severity ($p < 0.05$). It would also
517 appear that no matter where an individual is, what his/her age is, and everything that characterizes the person from
518 birth, are not ultimately the main characteristics to be taken into consideration concerning the COVID-19 infection
519 (and severity). Despite the limitations, based on our results this is the first study that demonstrated that it would be
520 much more the lifestyle of the individual that decides a potential infection. Therefore, we strongly encourage the
521 world population to adopt a healthy lifestyle: no alcohol, no tobacco, or at least reducing their consumption; eat

522 healthily, sleep well and practice regularly a physical activity, in addition to a massive vaccination, specifically for
523 medical staff and people at risk. Finally, the capital points not to be neglected will inevitably remain the fact of avoid-
524 ing as much as possible any gathering (apply social distancing, in particular by using remote working to the maxi-
525 mum extent possible) and observe the protective measures promoted by the WHO. Further studies remain necessary
526 to help fighting against the constantly evolving epidemiological situation. In the end, we hope that this positive mes-
527 sage that we deliver (supported by results) can positively influence the behavior of people while waiting for the
528 health crisis to subside and for the world to return to normality.

529 **Author Contributions:** Conceptualization, H.A.A., M.A. and A-I.P.; methodology, H.A.A., M.A. and A-I.P.; validation, C.M.L., L.E.
530 and N.O.; formal analysis, H.A.A., A-I.P., L.E. and N.O.; investigation, H.A.A. and M.A.; resources, A.S., M.S.A.K.; data curation,
531 M.A. and A-I.P., writing—original draft preparation, H.A.A., A-I.P., J.Y. and L.E.; writing—review and editing, H.A.A., A-I.P., A.S.,
532 J.Y. and N.O.; visualization, C.M.L., L.E. and N.O. supervision, A-I.P., L.E. and N.O.; project administration, M.S.E.K.; funding ac-
533 quisition, H.A.A., A.S., and M.S.E.K. All authors have read and agreed to the published version of the manuscript.

534 **Funding:** This research was funded by the DGRSDT and the MESRS.

535 **Institutional Review Board Statement:** Not applicable.

536 **Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study and all procedures were
537 approved by the CRSTRA.

538
539 **Data Availability Statement:** The data generated and/or analyzed in the current study is available from the corresponding author
540 on reasonable request.

541 **Acknowledgments:** Considerable appreciation is addressed to the DGRSDT (Directorate-General of Scientific Research and Tech-
542 nological Development of Algeria) and the MESRS (Ministry of Higher Education and Scientific Research of Algeria) for their val-
543 uable support. The authors thank, as well, all of the respondents in this study for their voluntary participation and for providing
544 such essential information. Many thanks are also addressed to anyone who helped us by sharing the questionnaire.

545 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collec-
546 tion, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

547 References

- 548
- 549 1. Cui, J.; Li, F.; Shi, ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol* **2019**, *17*, 181–192.
550 <https://doi.org/10.1038/s41579-018-0118-9>
- 551 2. Yang, W.; Sirajuddin, A.; Zhang, X.; Liu, G.; Teng, Z.; Zhao, S.; Lu, M. The role of imaging in 2019 novel coronavirus
552 pneumonia (COVID-19). *European radiology* **2020**, *30*(9), 4874–4882. <https://doi.org/10.1007/s00330-020-06827-4>
- 553 3. Wu, Y.; Feng, Z.; Li, P.; Yu, Q. Relationship between ABO blood group distribution and clinical characteristics in patients
554 with COVID-19. *Clin. Chim. Acta* **2020**, *509*, 220–223. <https://doi.org/10.1016/j.cca.2020.06.026>
- 555 4. Yasuhara, J.; Kuno, T.; Takagi, H.; Sumitomo, N. Clinical characteristics of COVID-19 in children: A systematic review.
556 *Pediatr Pulmonol.* **2020**, *55*(10), 2565–2575. <https://doi.org/10.1002/ppul.24991>
- 557 5. Deng, S. Q.; Peng, H. J. Characteristics of and public health responses to the coronavirus disease, outbreak in China. *J. Clin.*
558 *Med.* **2020**, *9*, 575. <https://doi.org/10.3390/jcm9020575>
- 559 6. World Health Organization. Novel coronavirus (2019-nCoV) situation reports. Available from:
560 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports> **2021**.
- 561 7. Van Damme, W.; Dahake, R.; Delamou, A.; Ingelbeen, B.; Wouters, E.; Vanham, G. et al. The COVID-19 pandemic: diverse
562 contexts; different epidemics-how and why?. *BMJ global health* **2020**, *5*(7), e003098.
563 <https://doi.org/10.1136/bmjgh-2020-003098>
- 564 8. Wong, J.; Goh, Q. Y.; Tan, Z.; Lie, S. A.; Tay, Y. C.; Ng, S. Y. et al. Preparing for a COVID-19 pandemic: a review of operat-
565 ing room outbreak response measures in a large tertiary hospital in Singapore. *Canadian journal of anaesthesia* **2020**, *67*(6),
566 732–745. <https://doi.org/10.1007/s12630-020-01620-9>
- 567 9. Xiang, Y. T.; Yang, Y.; Li, W.; Zhang, L.; Zhang, Q.; Cheung, T. et al. Timely mental health care for the 2019 novel corona-
568 virus outbreak is urgently needed. *Lancet Psychiatry* **2020**, *7*(3), 228–229. [https://doi.org/10.1016/s2215-0366\(20\)30046-8](https://doi.org/10.1016/s2215-0366(20)30046-8)
- 569 10. Gautret, P.; Lagier, J. C.; Parola, P.; Hoang, V. T.; Meddeb, L.; Mailhe, et al. Hydroxychloroquine and azithromycin as a
570 treatment of COVID-19: results of an open-label non-randomized clinical trial. *International journal of antimicrobial agents*
571 **2020**, *56*(1), 105949. <https://doi.org/10.1016/j.ijantimicag.2020.105949>
- 572 11. Aouissi, H.A.; Ababsa, M.; Gaagai, A. Review of a controversial treatment method in the fight against COVID-19 with the
573 example of Algeria. *Bulletin of the National Research Centre* **2021**, *45*(1), 94. <https://doi.org/10.1186/s42269-021-00550-w>
- 574 12. Batiha, G. E.; Zayed, M. A.; Awad, A.A.; Shaheen, H. M.; Mustapha, S.; Herrera-Calderon, O. et al. Management of
575 SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19. *Frontiers in medicine* **2021**, *8*, 642313.
576 <https://doi.org/10.3389/fmed.2021.642313>
- 577 13. Norrie, J. D. Remdesivir for COVID-19: challenges of underpowered studies. *The Lancet* **2020**, *395*(10236), 1525–1527.
578 [https://doi.org/10.1016/S0140-6736\(20\)31023-0](https://doi.org/10.1016/S0140-6736(20)31023-0)

- 579 14. Beigel, J. H.; Tomashek, K. M.; Dodd, L. E.; Mehta, A. K.; Zingman, B. S.; Kalil, A. C. et al. Remdesivir for the Treatment
580 of Covid-19 - Final Report. *The New England journal of medicine* **2020**, 383(19), 1813–1826.
581 <https://doi.org/10.1056/NEJMoa2007764>
- 582 15. Coomes, E. A.; Haghbayan, H. Favipiravir, an antiviral for COVID-19?. *The Journal of antimicrobial chemotherapy* **2020**,
583 75(7), 2013–2014. <https://doi.org/10.1093/jac/dkaa171>
- 584 16. RECOVERY Collaborative Group; Horby, P.; Lim, W. S.; Emberson, J. R.; Mafham, M.; Bell, J. L. et al. Dexamethasone in
585 Hospitalized Patients with Covid-19. *The New England journal of medicine* **2021**, 384(8), 693–704.
586 <https://doi.org/10.1056/NEJMoa2021436>
- 587 17. Gendrot, M.; Dufлот, I.; Boxberger, M.; Delandre, O.; Jardot, P.; Le Bideau, et al. Antimalarial artemisinin-based combina-
588 tion therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.
589 *International journal of infectious diseases* **2020**, 99, 437–440. <https://doi.org/10.1016/j.ijid.2020.08.032>
- 590 18. Schmith, V. D.; Zhou, J. J.; Lohmer, L. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of
591 COVID-19. *Clinical pharmacology and therapeutics* **2020**, 108(4), 762–765. <https://doi.org/10.1002/cpt.1889>
- 592 19. Roussel, R.; Darmon, P.; Pichelin, M.; Goronflot, T.; Abouleka, Y.; Ait Bachir, L. et al. Use of dipeptidyl peptidase-4 inhib-
593 itors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the
594 CORONADO study. *Diabetes, obesity & metabolism* **2021**, 23(5), 1162–1172. <https://doi.org/10.1111/dom.14324>
- 595 20. Thanh Le, T.; Andreadakis, Z.; Kumar, A.; Gómez Román, R.; Tollefsen, S.; Saville, M. et al. The COVID-19 vaccine de-
596 velopment landscape. *Nature reviews. Drug discovery* **2020**, 19(5), 305–306. <https://doi.org/10.1038/d41573-020-00073-5>
- 597 21. Graham, B.S. Rapid COVID-19 vaccine development. *Science* **2020**, 368(6494), 945–946.
598 <https://doi.org/10.1126/science.abb8923>
- 599 22. Mathieu, E.; Ritchie, H.; Ortiz-Ospina, E.; Roser, M.; Hasell, J.; Appel, C. et al. A global database of COVID-19 vaccina-
600 tions. *Nature human behavior* **2021**, 5(7), 947–953. <https://doi.org/10.1038/s41562-021-01122-8>
- 601 23. Shay, D. K.; Gee, J.; Su, J. R.; Myers, T. R.; Marquez, P.; Liu, R. et al. Safety Monitoring of the Janssen (Johnson & Johnson)
602 COVID-19 Vaccine - United States, March-April 2021. *MMWR. Morbidity and mortality weekly report* **2021**, 70(18), 680–684.
603 <https://doi.org/10.15585/mmwr.mm7018e2>
- 604 24. Livingston, E. H.; Malani, P. N.; Creech, C. B. The Johnson & Johnson Vaccine for COVID-19. *JAMA* **2021**, 325(15),
605 1575–1575. <https://doi.org/10.1001/jama.2021.2927>
- 606 25. Oliver, S. E.; Gargano, J. W.; Marin, M.; Wallace, M.; Curran, K. G.; Chamberland, M. et al. The Advisory Committee on
607 Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, De-
608 cember 2020. *MMWR. Morbidity and mortality weekly report* **2020**, 69(50), 1922–1924.
609 <https://doi.org/10.15585/mmwr.mm6950e2>
- 610 26. Britton, A.; Jacobs Slifka, K.M.; Edens, C.; Nanduri, S.A.; Bart, S.M.; Shang, N. et al. Effectiveness of the Pfizer-BioNTech
611 COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut,
612 December 2020-February 2021. *MMWR. Morbidity and mortality weekly report* **2021**, 70(11), 396–401.
613 <https://doi.org/10.15585/mmwr.mm7011e3>
- 614 27. Mahase, E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. *BMJ:*
615 *British Medical Journal* **2020**, 371. <https://doi.org/10.1136/bmj.m4471>
- 616 28. Callaway, E. COVID vaccine excitement builds as Moderna reports third positive result. *Nature* **2020**, 587(7834), 337–338.
617 <https://doi.org/10.1038/d41586-020-03248-7>
- 618 29. Vogel, G.; Kupferschmidt, K. Side effect worry grows for AstraZeneca vaccine. *Science* **2021**, 372(6537), 14–15.
619 <https://doi.org/10.1126/science.372.6537.14>
- 620 30. Knoll, M.D.; Wonodi, C. Oxford-AstraZeneca COVID-19 vaccine efficacy. *The Lancet* **2021**, 397(10269), 72–74.
621 [https://doi.org/10.1016/S0140-6736\(20\)32623-4](https://doi.org/10.1016/S0140-6736(20)32623-4)
- 622 31. Logunov, D.Y.; Dolzhikova, I.V.; Shcheplyakov, D.V.; Tukhvatulin, A. I.; Zubkova, O.V.; Dzharullaeva, A.S. et al. Safety
623 and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a
624 randomised controlled phase 3 trial in Russia. *The Lancet* **2021**, 397(10275), 671–681.
625 [https://doi.org/10.1016/S0140-6736\(21\)00234-8](https://doi.org/10.1016/S0140-6736(21)00234-8)
- 626 32. Jones, I.; Roy, P. Sputnik V COVID-19 vaccine candidate appears safe and effective. *The Lancet* **2021**, 397(10275), 642–643.
627 [https://doi.org/10.1016/S0140-6736\(21\)00191-4](https://doi.org/10.1016/S0140-6736(21)00191-4)
- 628 33. Mallapaty, S. China COVID vaccine reports mixed results - what does that mean for the pandemic?, *Nature* **2021**, Ad-
629 vance online publication. <https://doi.org/10.1038/d41586-021-00094-z>
- 630 34. Forni, G.; Mantovani, A.; COVID-19 Commission of Accademia Nazionale dei Lincei, Rome COVID-19 vaccines: where
631 we stand and challenges ahead. *Cell death and differentiation* **2021**, 28(2), 626–639.
632 <https://doi.org/10.1038/s41418-020-00720-9>
- 633 35. Cohen, J. China's vaccine gambit. *Science* **2020**, 370(6522), 1263–1267. <https://doi.org/10.1126/science.370.6522.1263>
- 634 36. Ella, R.; Vadrevu, K.M.; Jogdand, H.; Prasad, S.; Reddy, S.; Sarangi, V. et al. Safety and immunogenicity of an inactivated
635 SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. *The Lancet Infectious diseases* **2021**, 21(5), 637–646.
636 [https://doi.org/10.1016/S1473-3099\(20\)30942-7](https://doi.org/10.1016/S1473-3099(20)30942-7)
- 637 37. Palacios, R.; Patiño, E. G.; de Oliveira Piorelli, R.; Conde, M.; Batista, A. P.; Zeng, G. et al. Double-Blind, Randomized,
638 Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with
639 the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a
640 study protocol for a randomised controlled trial. *Trials* **2020**, 21(1), 853. <https://doi.org/10.1186/s13063-020-04775-4>

- 641 38. Jara, A.; Undurraga, E.A.; González, C.; Paredes, F.; Fontecilla, T.; Jara, G. et al. Effectiveness of an Inactivated
642 SARS-CoV-2 Vaccine in Chile. *The New England journal of medicine* **2021**, NEJMoa2107715.
643 <https://doi.org/10.1056/NEJMoa2107715>
- 644 39. Lopez Bernal, J.; Andrews, N.; Gower, C.; Gallagher, E.; Simmons, R.; Thelwall, S. et al. Effectiveness of Covid-19 Vac-
645 cines against the B.1.617.2 (Delta) Variant. *The New England journal of medicine* **2021**, NEJMoa2108891.
646 <https://doi.org/10.1056/NEJMoa2108891>
- 647 40. Zhao, X.; Li, D.; Ruan, W.; Zhang, R.; Zheng, A.; Qiao, S.; Zheng, X.; Zhao, Y.; Chen, Z.; Dai, L. Han, P.; Gao, G.F. Re-
648 duced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convales-
649 cents. *bioRxiv*, **2021**.
- 650 41. Mahase, E. Covid-19: Vaccine brands can be mixed in "extremely rare occasions," says Public Health England. *BMJ (Clini-
651 cal research ed.)* **2021**, 372, n12. <https://doi.org/10.1136/bmj.n12>
- 652 42. Aouissi HA. Algeria's preparedness for Omicron variant and for the fourth wave of COVID-19. *Glob Health Med.* **2021**,
653 3(6), 413-414. <https://doi.org/10.35772/ghm.2021.01117>
- 654 43. Balanzá-Martínez, V.; Kapczinski, F.; de Azevedo Cardoso, T.; Atienza-Carbonell, B.; Rosa, A.R.; Mota, J.C. et al. The as-
655 sessment of lifestyle changes during the COVID-19 pandemic using a multidimensional scale. *Revista de psiquiatria y salud
656 mental* **2021**, 14(1), 16–26. <https://doi.org/10.1016/j.rpsm.2020.07.003>
- 657 44. Garre-Olmo, J.; Turró-Garriga, O.; Martí-Lluch, R.; Zacarías-Pons, L.; Alves-Cabratos, L.; Serrano-Sarboza, D. et al.
658 Changes in lifestyle resulting from confinement due to COVID-19 and depressive symptomatology: A cross-sectional a
659 population-based study. *Comprehensive psychiatry* **2021**, 104, 152214. <https://doi.org/10.1016/j.comppsy.2020.152214>
- 660 45. Geldsetzer, P. Knowledge and Perceptions of COVID-19 Among the General Public in the United States and the United
661 Kingdom: A Cross-sectional Online Survey. *Annals of internal medicine* **2020**, 173(2), 157–160.
662 <https://doi.org/10.7326/M20-0912>
- 663 46. Agarwal, A.; Ranjan, P.; Rohilla, P.; Saikaustubh, Y.; Sahu, A.; Dwivedi, S.N. et al. Development and validation of a ques-
664 tionnaire to assess preventive practices against COVID-19 pandemic in the general population. *Preventive medicine reports*
665 **2021**, 22, 101339. <https://doi.org/10.1016/j.pmedr.2021.101339>
- 666 47. Pan, K.Y.; Kok, A.; Eikelenboom, M.; Horsfall, M.; Jörg, F.; Luteijn, R.A. et al. The mental health impact of the COVID-19
667 pandemic on people with and without depressive, anxiety, or obsessive-compulsive disorders: a longitudinal study of
668 three Dutch case-control cohorts. *The lancet. Psychiatry* **2021**, 8(2), 121–129. [https://doi.org/10.1016/S2215-0366\(20\)30491-0](https://doi.org/10.1016/S2215-0366(20)30491-0)
- 669 48. Chopra, S.; Ranjan, P.; Malhotra, A.; Sahu, A.; Dwivedi, S.N.; Baitha, U. et al. Development and validation of a question-
670 naire to evaluate the impact of COVID-19 on lifestyle-related behaviours: eating habits, activity and sleep behaviour. *Pub-
671 lic health nutrition* **2021**, 24(6), 1275–1290. <https://doi.org/10.1017/S1368980020004656>
- 672 49. Yan, S.; Xu, R.; Stratton, T.D.; Kavcic, V.; Luo, D.; Hou, F. et al. Sex differences and psychological stress: responses to the
673 COVID-19 pandemic in China. *BMC public health* **2021**, 21(1), 79. <https://doi.org/10.1186/s12889-020-10085-w>
- 674 50. Kobayashi, L.C.; O'Shea, B.Q.; Kler, J.S.; Nishimura, R.; Palavicino-Maggio, C.B.; Eastman, M.R. et al. Cohort profile: the
675 COVID-19 Coping Study, a longitudinal mixed-methods study of middle-aged and older adults' mental health and
676 well-being during the COVID-19 pandemic in the USA. *BMJ open* **2021**, 11(2), e044965.
677 <https://doi.org/10.1136/bmjopen-2020-044965>
- 678 51. Moulin, F.; El-Aarbaoui, T.; Bustamante, J.; Héron, M.; Mary-Krause, M.; Rouquette, A. et al. Risk and protective factors
679 related to children's symptoms of emotional difficulties and hyperactivity/inattention during the COVID-19-related
680 lockdown in France: results from a community sample. *European child & adolescent psychiatry* **2021**, 1–12.
681 <https://doi.org/10.1007/s00787-021-01752-3>
- 682 52. Zhou, F.; You, C.; Zhang, X.; Qian, K.; Hou, Y.; Gao, Y. et al. Epidemiological Characteristics and Factors Associated with
683 Critical Time Intervals of COVID-19 in Eighteen Provinces, China: A Retrospective Study. *International journal of infectious
684 diseases* **2021**, 102, 123–131. <https://doi.org/10.1016/j.ijid.2020.09.1487>
- 685 53. Wolff, D.; Nee, S.; Hickey, N.S.; Marschollek, M. Risk factors for Covid-19 severity and fatality: a structured literature re-
686 view. *Infection* **2021**, 49(1), 15–28. <https://doi.org/10.1007/s15010-020-01509-1>
- 687 54. Islam, F.M.A.; Walton, A. Tobacco smoking and use of smokeless tobacco and their association with psychological dis-
688 tress and other factors in a rural district in Bangladesh: A cross-sectional study. *Journal of environmental and public health*
689 **2019**, 1424592. <https://doi.org/10.1155/2019/1424592>
- 690 55. Yingst, J.M.; Krebs, N.M.; Bordner, C.R.; Hobkirk, A.L.; Allen, S.I.; Foulds, J. Tobacco Use Changes and Perceived Health
691 Risks among Current Tobacco Users during the COVID-19 Pandemic. *International Journal of Environmental Research and
692 Public Health* **2021**, 18(4), 1795. <https://doi.org/10.3390/ijerph18041795>
- 693 56. Kim, L.; Garg, S.; O'Halloran, A.; Whitaker, M.; Pham, H.; Anderson, E. J. et al. Risk Factors for Intensive Care Unit Ad-
694 mission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019
695 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). *Clinical infectious diseases* **2021**, 72(9),
696 e206–e214. <https://doi.org/10.1093/cid/ciaa1012>
- 697 57. Ko, J. Y.; Danielson, M.L.; Town, M.; Derado, G.; Greenlund, K.J.; Kirley, P.D. et al. Risk factors for coronavirus disease
698 2019 (COVID-19)-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral
699 risk factor surveillance system. *Clinical Infectious Diseases* **2021**, 72(11), e695-e703. <https://doi.org/10.1093/cid/ciaa1419>
- 700 58. Berlin, I.; Thomas, D.; Le Faou, A.L.; Cornuz, J. COVID-19 and smoking. *Nicotine and Tobacco Research* **2020**, 22(9),
701 1650-1652 <https://doi.org/10.1093/ntr/ntaa059>

- 702 59. Mistry, S.K.; Ali, A.M.; Rahman, M.A.; Yadav, U.N.; Gupta, B. et al. Changes in Tobacco Use Patterns during COVID-19
703 and Their Correlates among Older Adults in Bangladesh. *International Journal of Environmental Research and Public Health*
704 **2021**, *18*(4), 1779. <https://doi.org/10.3390/ijerph18041779>
- 705 60. Simou, E.; Britton, J.; Leonardi-Bee, J. Alcohol and the risk of pneumonia: a systematic review and meta-analysis. *BMJ*
706 *open* **2018**, *8*(8), e022344. <https://doi.org/10.1136/bmjopen-2018-022344>
- 707 61. Abuga, K.; Nyamweya, N. Alcohol-Based Hand Sanitizers in COVID-19 Prevention: A Multidimensional Perspective.
708 *Pharmacy* **2021**, *9*(1), 64. <https://doi.org/10.3390/pharmacy9010064>
- 709 62. Da, B. L.; Im, G. Y.; Schiano, T. D. Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alco-
710 hol-Associated Liver Disease. *Hepatology* **2020**, *72*(3), 1102–1108. <https://doi.org/10.1002/hep.31307>
- 711 63. Testino, G. Are Patients With Alcohol Use Disorders at Increased Risk for Covid-19 Infection?. *Alcohol and alcoholism* **2020**,
712 *55*(4), 344–346. <https://doi.org/10.1093/alcalc/agaa037>
- 713 64. Heidari, M.; Sayfour, N. COVID-19 and Alcohol Poisoning: A Fatal Competition. *Disaster Medicine and Public Health Pre-
714 paredness* **2021**, 1–3. <https://doi.org/10.1017/dmp.2021.89>
- 715 65. Hassanian-Moghaddam, H.; Pajoumand, A.; Dadgar, S. M.; Shadnia, S. H. Prognostic factors in methanol poisoning. *Hu-
716 man & experimental toxicology* **2007**, *26*(7), 583–586. <https://doi.org/10.1177/0960327106080077>
- 717 66. Lassen, M.C.H.; Skaarup, K.G.; Sengeløv, M.; Iversen, K.; Ulrik, C.S.; Jensen, J.U.S et al. Alcohol Consumption and the
718 Risk of Acute Respiratory Distress Syndrome in COVID-19. *Annals of the American Thoracic Society* **2020**, *18*(6), 1074–1076.
719 <https://doi.org/10.1513/AnnalsATS.202008-988RL>
- 720 67. Wong, C-M.; Lai, H-K.; OU, C-Q.; Ho, S.Y.; Chan, K.P; Thach, T.Q. et al. Is Exercise Protective Against Influen-
721 za-Associated Mortality?. *PLoS one* **2008**, *2*; 3: e2108. <https://doi.org/10.1371/journal.pone.0002108>
- 722 68. Lowder, T.; Padgett, D.A.; Woods, J.A. Moderate exercise protects mice from death due to influenza virus. *Brain Behav*
723 *Immun.* **2005**, *19*: 377-380. <https://doi.org/10.1016/j.bbi.2005.04.002>
- 724 69. Zimmer, P.; Schenk, A.; Kieven, M.; Holthaus, M.; Lehmann, J.; Lövenich, L. et al. Exercise induced alterations in NK-cell
725 cytotoxicity - methodological issues and future perspectives. *Exercise immunology review* **2017**, *23*, 66–81.
- 726 70. Wackerhage, H.; Everett, R.; Krüger, K.; Murgia, M.; Simon, P.; Gehlert, S. et al. Sport, exercise and COVID-19, the disease
727 caused by the SARS-CoV-2 coronavirus. *Dtsch. Z. Sportmed* **2020**, *71*(5), e1-12. <https://doi.org/10.5960/dzsm.2020.441>
- 728 71. Narici, M.; Vito, G.; Franchi, M.; Paoli, A.; Moro, T.; Marcolin, G. et al. Impact of sedentarism due to the COVID-19 home
729 confinement on neuromuscular, cardiovascular and metabolic health: Physiological and pathophysiological implications
730 and recommendations for physical and nutritional countermeasures. *European journal of sport science* **2021**, *21*(4), 614–635.
731 <https://doi.org/10.1080/17461391.2020.1761076>
- 732 72. Hammami, A.; Harrabi, B.; Mohr, M.; Krusturup, P. Physical activity and coronavirus disease 2019 (COVID-19): specific
733 recommendations for home-based physical training, *Managing Sport and Leisure* **2020**,
734 <https://doi.org/10.1080/23750472.2020.1757494>
- 735 73. Polero, P.; Rebollo-Seco, C.; Adsuar, J. C.; Pérez-Gómez, J.; Rojo-Ramos, J.; Manzano-Redondo, F., et al. Physical Activity
736 Recommendations during COVID-19: Narrative Review. *International Journal of Environmental Research and Public Health*
737 **2020**, *18*(1), 65. <https://doi.org/10.3390/ijerph18010065>
- 738 74. Li, J.; Wang, X.; Chen, J.; Cai, Y.; Deng, A.; Yang, M. Association between ABO blood groups and risk of SARS-CoV-2
739 pneumonia. *British journal of haematology* **2020**, *190*(1), 24–27. <https://doi.org/10.1111/bjh.16797>
- 740 75. Anderson, J.L.; May, H.T.; Knight, S.; Bair, T. L.; Muhlestein, J.B.; Knowlton, K.U. et al. Association of Sociodemographic
741 Factors and Blood Group Type With Risk of COVID-19 in a US Population. *JAMA Network Open* **2021**, *4*(4),
742 e217429–e217429. <https://doi.org/10.1001/jamanetworkopen.2021.7429>
- 743 76. Goel, R.; Bloch, E.M.; Pirenne, F.; Al-Riyami, A.Z.; Crowe, E.; Dau, L. et al. ABO blood group and COVID-19: a review on
744 behalf of the ISBT COVID-19 working group. *Vox sanguinis* **2021**. <https://doi.org/10.1111/vox.13076>
- 745 77. Miotto, M.; Di Rienzo, L.; Gosti, G.; Milanetti, E.; Ruocco, G. Does blood type affect the COVID-19 infection pattern?. *PLoS*
746 *one* **2021**, *16*(5): e0251535. <https://doi.org/10.1371/journal.pone.0251535>
- 747 78. Bhopal, R.S. Migration, ethnicity, race, and health in multicultural societies. Oxford University Press: Oxford. UK. **2014**
- 748 79. Yancy, C.W. COVID-19 and African Americans. *JAMA* **2020**, May 19;323(19):1891-1892.
749 <https://doi.org/10.1001/jama.2020.6548>
- 750 80. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E. et al. Factors associated with
751 COVID-19-related death using OpenSAFELY. *Nature* **2020**, *584*(7821), 430–436. <https://doi.org/10.1038/s41586-020-2521-4>
- 752 81. Katikireddi, S.V.; Lal, S.; Carrol, E.D.; Niedzwiedz, C.L.; Khunti, K.; Dundas, R. et al. Unequal impact of the COVID-19
753 crisis on minority ethnic groups: a framework for understanding and addressing inequalities. *J Epidemiol Community*
754 *Health* **2021**, jech-2020-216061 <https://doi.org/10.1136/jech-2020-216061>
- 755 82. Sze, S.; Pan, D.; Nevill, C.R.; Gray, L.J.; Martin, C.A.; Nazareth, J.; Minhas, J.S.; Divall, P.; Khunti, K.; Abrams, K.R.;
756 Nellums, L.B.; Pareek, M. Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis.
757 *EclinicalMedicine* **2020**, *29*, 100630. <https://doi.org/10.1016/j.eclinm.2020.100630>
- 758 83. Vist, G.E.; Arentz-Hansen, E.H.; Vedoy, T.F.; Spilker, R.A.C.S.; Hafstad, E.V.; Giske, L. Incidence and severe outcomes
759 from COVID-19 among immigrant and minority ethnic groups and among groups of different socio-economic status: A
760 systematic review. **2021**. Url: <https://hdl.handle.net/11250/2754026>
- 761 84. Nacher, M.; Rousseau, C.; Succo, T.; Andrieu, A.; Gaillet, M.; Michaud, C. et al. The Epidemiology of COVID 19 in the
762 Amazon and the Guianas: Similarities, Differences, and International Comparisons. *Frontiers in public health* **2021**, *9*,
763 586299. <https://doi.org/10.3389/fpubh.2021.586299>

- 764 85. Dehingia, N.; Raj, A. Sex differences in COVID-19 case fatality: do we know enough?. *The Lancet Global Health* **2021**, 9(1),
765 e14-e15. [https://doi.org/10.1016/S2214-109X\(20\)30464-2](https://doi.org/10.1016/S2214-109X(20)30464-2)
- 766 86. Judah, G.; Anger, R.; Schmidt, W.P.; Michie, S.; Granger, S.; Curtis, V. Experimental pretesting of hand-washing inter-
767 ventions in a natural setting. *American journal of public health* **2009**, 99(S2), S405-S411.
768 <https://doi.org/10.1038/s41467-020-19741-6>
- 769 87. Peckham, H.; de Grujter, N.M.; Raine, C.; Radziszewska, A.; Ciurtin, C.; Wedderburn, L.R. et al. Male sex identified by
770 global COVID-19 meta-analysis as a risk factor for death and ICU admission. *Nature communications* **2020**, 11(1), 6317.
771 <https://doi.org/10.1038/s41467-020-19741-6>
- 772 88. Raimondi, F.; Novelli, L.; Ghirardi, A.; Russo, F.M.; Pellegrini, D.; Biza, R. et al. Covid-19 and gender: lower rate but same
773 mortality of severe disease in women-an observational study. *BMC pulmonary medicine* **2021**, 21(1), 96.
774 <https://doi.org/10.1186/s12890-021-01455-0>
- 775 89. Joe, W.; Kumar, A.; Rajpal, S.; Mishra, U.; Subramanian, S.V. Equal risk, unequal burden? Gender differentials in
776 COVID-19 mortality in India. *J Glob Health Sci* **2020**, 2(1):e17. <https://doi.org/10.35500/jghs.2020.2.e17>
- 777 90. Bhopal, S.S.; Bhopal, R. Sex differential in COVID-19 mortality varies markedly by age. *The Lancet* **2020**. 396(10250),
778 532–533. [https://doi.org/10.1016/S0140-6736\(20\)31748-7](https://doi.org/10.1016/S0140-6736(20)31748-7)
- 779 91. Wang, Y.; Pang, S.C.; Yang, Y. A potential association between immunosenescence and high COVID-19 related mortality
780 among elderly patients with cardiovascular diseases. *Immun Ageing* **2021**, 18, 25
781 <https://doi.org/10.1186/s12979-021-00234-z>
- 782 92. Porcheddu, R.; Serra, C.; Kelvin, D.; Kelvin, N.; Rubino, S. Similarity in Case Fatality Rates (CFR) of
783 COVID-19/SARS-COV-2 in Italy and China, *J Infect Dev Ctries* **2020**, 14:125-128. <https://doi.org/10.3855/jidc.12600>
- 784 93. Bonanad, C.; Garcia-Blas, S.; Tarazona-Santabalbina, F.; Sanchis, J.; Bertomeu-González, V.; Facila, L. et al. The effect of
785 age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. *Journal of the American Medical Direc-*
786 *tors Association* **2020**, 21(7), 915-918. <https://doi.org/10.1016/j.jamda.2020.05.045>
- 787 94. Aouissi, H.A.; Belhaouchet, I. What about rheumatic diseases and COVID-19?. *New microbes and new infections* **2021**, 41,
788 100846. <https://doi.org/10.1016/j.nmni.2021.100846>
- 789 95. Cox, L.S.; Bellantuono, I.; Lord, J.M.; Sapey, E.; Mannick, J.B.; Partridge, L. et al. Tackling Immunosenescence to improve
790 COVID-19 outcomes and vaccine response in older adults. *The Lancet Healthy Longevity* **2020**, 1(2), e55-e57.
791 [https://doi.org/10.1016/S2666-7568\(20\)30011-8](https://doi.org/10.1016/S2666-7568(20)30011-8)
- 792 96. Genebat, M.; Tarancón-Díez, L.; De Pablo-Bernal, R.; Calderón, A.; Muñoz-Fernández, M.Á.; Leal, M. Coronavirus Dis-
793 ease (COVID-19): a perspective from immunosenescence. *Aging and disease* **2021**, 12(1), 3.
794 <https://doi.org/10.14336/AD.2020.0831>
- 795 97. Pietrobon, A.J.; Teixeira, F.M.E.; Sato, M.N. Immunosenescence and inflammaging: Risk factors of severe covid-19 in old-
796 er people. *Frontiers in Immunology* **2020**, 11. <https://doi.org/10.3389/fimmu.2020.579220>
- 797 98. Sasson, I. Age and COVID-19 mortality: A comparison of Gompertz doubling time across countries and causes of death.
798 *Demographic Research* **2021**, 44, 379-396. <https://doi.org/10.4054/DemRes.2021.44.16>
- 799 99. Lim, M. Q.; Kumaran, E.A.; Tan, H.C.; Lye, D.C.; Leo, Y.S.; Ooi, E.E. et al. Cross-reactivity and anti-viral function of den-
800 gue capsid and NS3-specific memory T cells toward Zika virus. *Frontiers in immunology* **2018**, 9, 2225.
801 <https://doi.org/10.3389/fimmu.2018.02225>
- 802 100. Zhang, Q.; Bastard, P.; Liu, Z.; Le Pen, J.; Moncada-Velez, M.; Chen, J. et al. Inborn errors of type I IFN immunity in pa-
803 tients with life-threatening COVID-19. *Science* **2020**, 370(6515). <https://doi.org/10.1126/science.abd4570>
- 804 101. Bastard, P.; Rosen, L.B.; Zhang, Q.; Michailidis, E.; Hoffmann, H.H.; Zhang, Y. et al. Autoantibodies against type I IFNs in
805 patients with life-threatening COVID-19. *Science* **2020**, 370(6515). <https://doi.org/10.1126/science.abd4585>
- 806 102. Le Bert, N.; Tan, A.T.; Kunasegaran, K.; Tham, C.; Hafezi, M.; Chia, A. et al. SARS-CoV-2-specific T cell immunity in cases
807 of COVID-19 and SARS, and uninfected controls. *Nature* **2020**, 584(7821), 457–462.
808 <https://doi.org/10.1038/s41586-020-2550-z>
- 809 103. Van Damme, W.; Dahake, R.; Van de Pas, R.; Vanham, G.; Assefa, Y. COVID-19: Does the infectious inoculum
810 dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics?.
811 *Medical hypotheses* **2021**, 146, 110431. <https://doi.org/10.1016/j.mehy.2020.110431>
- 812 104. Fakhroo, A.D.; Al Thani, A.A.; Yassine, H.M. Markers Associated with COVID-19 Susceptibility, Resistance, and Severity.
813 *Viruses* **2020**, 13(1), 45. <https://doi.org/10.3390/v13010045>
- 814 105. Oshio, T.; Kan, M. Educational level as a predictor of the incidences of non-communicable diseases among middle-aged
815 Japanese: a hazards-model analysis. *BMC public health* **2019**, 19(1), 852. <https://doi.org/10.1186/s12889-019-7182-6>
- 816 106. Concepción-Zavaleta, M. J.; Coronado-Arroyo, J.C.; Zavaleta-Gutiérrez, F.E.; Concepción-Urteaga, L. A. Does level of ed-
817 ucation influence mortality of SARS-CoV-2 in a developing country?. *International Journal of Epidemiology* **2020**, 49(6),
818 2091–2093. <https://doi.org/10.1093/ije/dyaa193>
- 819 107. Lakshmi Priyadarini, S.; Suresh, M. Factors influencing the epidemiological characteristics of pandemic COVID 19: A
820 TISM approach. *International Journal of Healthcare Management* **2020**, 13(2), 89-98.
821 <https://doi.org/10.1080/20479700.2020.1755804>
- 822 108. Millett, G. A.; Jones, A.T.; Benkeser, D.; Baral, S.; Mercer, L.; Beyrer, C. et al. Assessing differential impacts of COVID-19
823 on Black communities. *Annals of Epidemiology* **2020**, 47, 37–44. <https://doi.org/10.1016/j.annepidem.2020.05.003>
- 824 109. Margolis, R. Educational differences in healthy behavior changes and adherence among middle-aged Americans. *Journal*
825 *of Health and Social Behavior* **2013**, 54(3), 353–368. <https://doi.org/10.1177/0022146513489312>

- 826 110. Friis, K.; Lasgaard, M.; Rowlands, G.; Osborne, R.H.; Maindal, H.T. Health literacy mediates the relationship between
827 educational attainment and health behavior: A Danish population-based study. *Journal of Health Communication* **2016**,
828 21(sup2), 54–60. <https://doi.org/10.1080/10810730.2016.1201175>
- 829 111. Upshaw, T.L.; Brown, C.; Smith, R.; Perri, M.; Ziegler, C.; Pinto, A.D. Social determinants of COVID-19 incidence and
830 outcomes: A rapid review. *PLoS one* **2021**, 16(3), e0248336. <https://doi.org/10.1371/journal.pone.0248336>
- 831 112. Lee, J.; Lim, H.; Allen, J.; Choi, G. Effects of Learning Attitudes and COVID-19 Risk Perception on Poor Academic Per-
832 formance among Middle School Students. *Sustainability* **2021**, 13(10):5541. <https://doi.org/10.3390/su13105541>
- 833 113. Aouissi, H.A. Hydroxychloroquine in the fight against covid-19-Hydroxychloroquine dans la lutte contre la covid-19-
834 *Maghr. J. Pure & Appl. Sci.* **2020**, 6 (2) 65-71. <https://doi.org/10.48383/JMIST.PRSM/mjpas-v6i2.22513>
- 835 114. An, B.Y.; Tang, S.Y. Lessons from COVID-19 responses in East Asia: Institutional infrastructure and enduring policy in-
836 struments. *The American Review of Public Administration* **2020**, 50(6-7), 790-800. <https://doi.org/10.1177/0275074020943707>
- 837 115. Kraemer, M.; Yang, C.H.; Gutierrez, B.; Wu, C.H.; Klein, B.; Pigott, D.M. et al. The effect of human mobility and control
838 measures on the COVID-19 epidemic in China. *MedRxiv* **2020**, 2020.03.02.20026708.
839 <https://doi.org/10.1101/2020.03.02.20026708>
- 840 116. Ababsa, M.; Aouissi, H.A. Current state of the coronavirus (Covid-19) in Algeria. *J Commun Med Health Care* **2020**,
841 5(1):1036. <https://doi.org/10.26420/jcommunitymedhealthcare.2020.1036>
- 842 117. McKenzie, G.; Adams, B. A country comparison of place-based activity response to COVID-19 policies. *Applied geography*
843 **2020**, 125, 102363. <https://doi.org/10.1016/j.apgeog.2020.102363>
- 844 118. Centers for Disease Control and Prevention. Protect yourself: coronavirus disease (COVID-19). Retrieved February 4,
845 **2021**, from <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html>
- 846 119. Combesse, J. C. La méthode de Sociologie, Chapter 4. Sondages, échantillons. Ed. La découverte. Coll. « Reperes», Paris,
847 France. **2007**, pp 45-54.
- 848 120. Arora, C.; Sinha, B.; Malhotra, A.; Ranjan, P. Development and validation of health education tools and evaluation ques-
849 tionnaires for improving patient care in lifestyle related diseases. *J Clin Diagn Res* **2017**, 11(5):JE06.
850 <https://doi.org/10.7860/ICDR/2017/28197.9946>
- 851 121. Reethesh, S.R.; Ranjan, P.; Arora, C.; Kalojya, G.S.; Vikram, N.K.; Dwivedi, S.N. et al. Development and validation of a
852 questionnaire assessing knowledge, attitude, and practices about obesity among obese individuals. *Indian J Endocr Metab*
853 **2019**, 23(1):102. https://doi.org/10.4103/ijem.IJEM_487_18
- 854 122. Pereltsvaig, A. Languages of the World: An Introduction, 2nd edition, Cambridge: Cambridge University Press.UK, **2017**.
855 <https://doi.org/10.1017/9781316758854>
- 856 123. Collett, D. Modelling Binary Data. 2nd edition. Chapman & Hall/CRC: London, UK, pp. 93.
857 <https://doi.org/10.1201/b16654>
- 858 124. Subedi, D.; Pantha, S.; Subedi, S.; Gautam, A.; Gaire, A.; Sapkota, D.; Sapkota, S.; Kandel, M.; Parajuli, A.; Ghimire, H.;
859 Ghimire, S.; Devkota, J.; Dhakal, S. Perceptions towards COVID-19 Vaccines and Willingness to Vaccinate in Nepal. *Vac-*
860 *cines* **2021**, 9, 1448. <https://doi.org/10.3390/vaccines9121448>
- 861 125. Shah, A. S.; Gribben, C.; Bishop, J.; Hanlon, P.; Caldwell, D.; Wood, R. et al. Effect of vaccination on transmission of
862 COVID-19: an observational study in healthcare workers and their households. *MedRxiv* **2021**.
863 <https://doi.org/10.1101/2021.03.11.21253275>
- 864 126. Lipsitch, M.; Kahn, R. Interpreting vaccine efficacy trial results for infection and transmission. *MedRxiv* **2021**,
865 2021.02.25.21252415. <https://doi.org/10.1101/2021.02.25.21252415>
- 866 127. Meier, K.; Glatz, T.; Guijt, M.C.; Piccininni, M.; Van der Meulen, M.; Atmar, K. et al. Public perspectives on protective
867 measures during the COVID-19 pandemic in the Netherlands, Germany and Italy: A survey study. *PLoS one* **2020**, 15(8),
868 e0236917. <https://doi.org/10.1371/journal.pone.0236917>
- 869 128. Abdulateef, D. S.; Rahman, H. S.; Salih, J. M.; Osman, S. M.; Mahmood, T.A.; Omer, S.; Ahmed, R.A. COVID-19 severity
870 in relation to sociodemographics and vitamin D use. *Open medicine* **2021**, 16(1), 591–609.
871 <https://doi.org/10.1515/med-2021-0273>
- 872 129. Sohn, M.; Koo, B.K.; Yoon, H.I.; Song, K. H.; Kim, E.S.; Kim, H.B.; Lim, S. Impact of COVID-19 and Associated Preventive
873 Measures on Cardiometabolic Risk Factors in South Korea. *Journal of obesity & metabolic syndrome* **2021**, 30(3), 248–260.
874 <https://doi.org/10.7570/jomes21046>
- 875 130. Rana, M. S.; Usman, M.; Alam, M. M.; Ikram, A.; Salman, M.; Zaidi, S.; Umair, M.; Qadir, M. Impact of COVID-19 preven-
876 tive measures on other infectious and non-infectious respiratory diseases in Pakistan. *The Journal of infection* **2021**, 82(5),
877 31–32. <https://doi.org/10.1016/j.jinf.2021.01.018>
- 878 131. Sugimura, M.; Chimed-Ochir, O.; Yumiya, Y.; Ohge, H.; Shime, N.; Sakaguchi, T.; Tanaka, J.; Takafuta, T.; Mimori, M.;
879 Kuwabara, M.; Asahara, T.; Kishita, E.; Kubo, T. The Association between Wearing a Mask and COVID-19. *Int. J. Environ.*
880 *Res. Public Health* **2021**, 18, 9131. <https://doi.org/10.3390/ijerph18179131>
- 881 132. Ramasamy, M.N.; Minassian, A.M.; Ewer, K.J.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R.; Voysey, M.; Aley, P.K.; An-
882 gus, B.; Babbage, G.; Bellij-Rammerstorfer, S.; Berry, L.; Bibi, S.; Bittaye, M.; Cathie, K.; Chappell, H.; Charlton, S.; Cicconi,
883 P.; Clutterbuck, E.A.; Colin-Jones, R.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1
884 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised,
885 controlled, phase 2/3 trial. *Lancet* **2021**, 396(10267), 1979–1993. [https://doi.org/10.1016/S0140-6736\(20\)32466-1](https://doi.org/10.1016/S0140-6736(20)32466-1)

- 886 133. O'Driscoll, M.; Ribeiro Dos Santos, G.; Wang, L.; Cummings, D.; Azman, A.S.; Paireau, J.; Fontanet, A.; Cauchemez, S.;
887 Salje, H. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*, **2021**, 590(7844), 140–145.
888 <https://doi.org/10.1038/s41586-020-2918-0>
- 889 134. Li, J.; Liao, X.; Zhou, Y.; Wang, L.; Yang, H.; Zhang, W.; Zhang, Z.; Kang, Y. Comparison of Associations Between Gluco-
890 corticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis.
891 *Shock* **2021**, 56(2), 215–228. <https://doi.org/10.1097/SHK.0000000000001738>
- 892 135. Gao, Y.D.; Ding, M.; Dong, X.; Zhang, J.J.; Kursat Azkur, A.; Azkur, D.; Gan, H.; Sun, Y.L.; Fu, W.; Li, W.; Liang, H.L.;
893 Cao, Y.Y.; Yan, Q.; Cao, C.; Gao, H.Y.; Brügggen, M.C.; Van de Veen, W.; Sokolowska, M.; Akdis, M.; Akdis, C.A. Risk fac-
894 tors for severe and critically ill COVID-19 patients: A review. *Allergy* **2021**, 76(2), 428–455. <https://doi.org/10.1111/all.14657>
- 895 136. Abbasi-Oshaghi, E.; Mirzaei, F.; Khodadadi, I. Alcohol Misuse May Increase the Severity of COVID-19 Infections. *Disaster*
896 *medicine and public health preparedness* **2020**, 1–2. <https://doi.org/10.1017/dmp.2020.452>
- 897 137. Hikida, S.; Morioka, S.; Fujii, N.; Tajima, T.; Terayama, Y.; Sugiura, Y. et al. A single-center descriptive study of untraced
898 sources of infection among new cases of coronavirus disease in Tokyo, Japan. *Global Health & Medicine* **2021**, 2021.01092.
899 <https://doi.org/10.35772/ghm.2021.01092>
- 900 138. González-Reimers, E.; Santolaria-Fernández, F.; Martín-González, M.C.; Fernández-Rodríguez, C.M.; Quintero-Platt, G.
901 Alcoholism: a systemic proinflammatory condition. *World journal of gastroenterology* **2014**, 20(40), 14660–14671.
902 <https://doi.org/10.3748/wjg.v20.i40.14660>
- 903 139. Dai, M.; Tao, L.; Chen, Z.; Tian, Z.; Guo, X.; Allen-Gipson, D.S. et al. Influence of Cigarettes and Alcohol on the Severity
904 and Death of COVID-19: A Multicenter Retrospective Study in Wuhan, China. *Frontiers in physiology* **2020**, 11, 588553.
905 <https://doi.org/10.3389/fphys.2020.588553>
- 906 140. Murthy, P.; Narasimha, V.L. Effects of the COVID-19 pandemic and lockdown on alcohol use disorders and complica-
907 tions. *Current opinion in psychiatry* **2021**, 34(4), 376–385 <https://doi.org/10.1097/YCO.0000000000000720>
- 908 141. Saengow, U.; Assanangkornchai, S.; Casswell, S. Alcohol: a probable risk factor of COVID-19 severity. *Addiction* **2021**,
909 116(1), 204–205. <https://doi.org/10.1111/add.15194>
- 910 142. Calina, D.; Hartung, T.; Mardare, I.; Mitroi, M.; Poulas, K.; Tsatsakis, A. et al. COVID-19 pandemic and alcohol consump-
911 tion: Impacts and interconnections. *Toxicology reports* **2021**, 8, 529–535. <https://doi.org/10.1016/j.toxrep.2021.03.005>
- 912 143. Reddy, R.K.; Charles, W.N.; Sklavounos, A.; Dutt, A.; Seed, P.T.; Khajuria, A. The effect of smoking on COVID-19 severi-
913 ty: A systematic review and meta-analysis. *Journal of medical virology* **2021**, 93(2), 1045–1056.
914 <https://doi.org/10.1002/jmv.26389>
- 915 144. Izcovich, A.; Ragusa, M.A.; Tortosa, F.; Lavena Marzio, M.A.; Agnoletti, C.; Bengolea, A.; Ceirano, A.; Espinosa, F.;
916 Saavedra, E.; Sanguine, V.; Tassara, A.; Cid, C.; Catalano, H.N.; Agarwal, A.; Foroutan, F.; Rada, G. Prognostic factors for
917 severity and mortality in patients infected with COVID-19: A systematic review. *PLoS one* **2020**, 15(11), e0241955.
918 <https://doi.org/10.1371/journal.pone.0241955>
- 919 145. Simons, D.; Shahab, L.; Brown, J.; Perski, O. The association of smoking status with SARS-CoV-2 infection, hospitalization
920 and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). *Addiction* **2021**,
921 116(6), 1319–1368. <https://doi.org/10.1111/add.15276>
- 922 146. Rozhnova, G.; Van Dorp, C.H.; Bruijning-Verhagen, P.; Bootsma, M.; Van de Wiggert, J.; Bonten, M. et al. Model-based
923 evaluation of school- and non-school-related measures to control the COVID-19 pandemic. *Nature communications* **2021**,
924 12(1), 1614. <https://doi.org/10.1038/s41467-021-21899-6>
- 925 147. Krishnaratne, S.; Pfadenhauer, L.M.; Coenen, M.; Geffert, K.; Jung-Sievers, C.; Klinger, C. et al. Measures implemented in
926 the school setting to contain the COVID-19 pandemic: a scoping review. *The Cochrane database of systematic reviews* **2020**,
927 12, CD013812. <https://doi.org/10.1002/14651858.CD013812>
- 928 148. Zhao, Y.; Liang, W.; Luo, Y.; Chen, Y.; Liang, P.; Zhong, R. et al. Personal protective equipment protecting healthcare
929 workers in the Chinese epicentre of COVID-19. *Clinical microbiology and infection: the official publication of the European Soci-
930 ety of Clinical Microbiology and Infectious Diseases* **2020**, 26(12), 1716–1718. <https://doi.org/10.1016/j.cmi.2020.07.029>
- 931 149. Canet-Vélez, O.; Botigué, T.; Lavedán Santamaría, A.; Masot, O.; Cemeli, T.; Roca, J. The perception of training and pro-
932 fessional development according to nursing students as health workers during COVID-19: A qualitative study. *Nurse ed-
933 ucation in practice* **2021**, 53, 103072. <https://doi.org/10.1016/j.nepr.2021.103072>
- 934 150. Thomson, S. Achievement at school and socioeconomic background—an educational perspective. *NPJ science of learning*
935 **2018**, 3, 5. <https://doi.org/10.1038/s41539-018-0022-0>
- 936 151. Destin, M.; Hanselman, P.; Buontempo, J.; Tipton, E.; Yeager, D.S. Do Student Mindsets Differ by Socioeconomic Status
937 and Explain Disparities in Academic Achievement in the United States?. *AERA open* **2019**, 5(3).
938 <https://doi.org/10.1177/2332858419857706>
- 939 152. Schultze, J. L.; Aschenbrenner, A.C. COVID-19 and the human innate immune system. *Cell* **2021**, 184(7), 1671–1692.
940 <https://doi.org/10.1016/j.cell.2021.02.029>
- 941 153. Chumakov, K.; Avidan, M.S.; Benn, C.S.; Bertozzi, S.M.; Blatt, L.; Chang, A.Y et al. Old vaccines for new infections: Ex-
942 ploiting innate immunity to control COVID-19 and prevent future pandemics. *Proceedings of the National Academy of Sci-
943 ences of the United States of America* **2021**, 118(21), e2101718118. <https://doi.org/10.1073/pnas.2101718118>
- 944 154. Kasuga, Y.; Zhu, B.; Jang, K.J.; Yoo, J.S. Innate immune sensing of coronavirus and viral evasion strategies. *Experimental &
945 molecular medicine* **2021**, 53(5), 723–736. <https://doi.org/10.1038/s12276-021-00602-1>
- 946 155. Franza, L.; Cianci, R. Pollution, Inflammation, and Vaccines: A Complex Crosstalk. *International journal of environmental
947 research and public health* **2021**, 18(12), 6330. <https://doi.org/10.3390/ijerph18126330>

- 948 156. Jaber, R.M.; Mafrachi, B.; Al-Ani, A.; Shkara, M. Awareness and perception of COVID-19 among the general population:
949 A Middle Eastern survey. *PLoS one* **2021**, *16*(4), e0250461. <https://doi.org/10.1371/journal.pone.0250461>
- 950 157. Bazaid, A.S.; Aldarhami, A.; Binsaleh, N.K.; Sherwani, S.; Althomali, O.W. Knowledge and practice of personal protective
951 measures during the COVID-19 pandemic: A cross-sectional study in Saudi Arabia. *PLoS one* **2020**, *15*(12), e0243695.
952 <https://doi.org/10.1371/journal.pone.0243695>
- 953 158. Binsaleh, N.K.; Bazaid, A.S.; Aldarhami, A.; Sherwani, S.; Althomali, O.W. Awareness and Practice of COVID-19 Precau-
954 tionary Measures Among Healthcare Professionals in Saudi Arabia. *Journal of multidisciplinary healthcare* **2021**, *14*,
955 1553–1560. <https://doi.org/10.2147/JMDH.S317908>
- 956 159. Medrano, M.; Cadenas-Sanchez, C.; Oses, M.; Arenaza, L.; Amasene, M.; Labayen, I. Changes in lifestyle behaviours dur-
957 ing the COVID-19 confinement in Spanish children: A longitudinal analysis from the MUGI project. *Pediatric obesity* **2021**,
958 *16*(4), e12731. <https://doi.org/10.1111/ijpo.12731>
- 959 160. He, M.; Xian, Y.; Lv, X.; He, J.; Ren, Y. Changes in Body Weight, Physical Activity, and Lifestyle During the
960 Semi-lockdown Period After the Outbreak of COVID-19 in China: An Online Survey. *Disaster medicine and public health*
961 *preparedness* **2020**, 1–6. <https://doi.org/10.1017/dmp.2020.237>
- 962 161. Aldhuwayhi, S.; Mallineni, S.K.; Sakhamuri, S.; Thakare, A.A.; Mallineni, S.; Sajja, R. et al. Covid-19 Knowledge and Per-
963 ceptions Among Dental Specialists: A Cross-Sectional Online Questionnaire Survey. *Risk management and healthcare policy*
964 **2021**, *14*, 2851–2861. <https://doi.org/10.2147/RMHP.S306880>
- 965 162. Chopra, S.; Ranjan, P.; Malhotra, A.; Sahu, A.; Dwivedi, S.N.; Baitha, U. et al. Development and validation of a question-
966 naire to evaluate the impact of COVID-19 on lifestyle-related behaviours: eating habits, activity and sleep behaviour. *Pub-
967 lic health nutrition* **2021**, *24*(6), 1275–1290. <https://doi.org/10.1017/S1368980020004656>
- 968 163. Komal, A.; Noreen, M.; Akhtar, J.; Imran, M.; Jamal, M.; Atif, M. et al. Analyses of ABO blood groups with susceptibility
969 and symptomatic variations of COVID-19 infection, a questionnaire-based survey. *APMIS: acta pathologica, microbiologica,
970 et immunologica Scandinavica* **2021**, 10.1111/apm.13169. <https://doi.org/10.1111/apm.13169>
- 971 164. Coccia, M. Factors determining the diffusion of COVID-19 and suggested strategy to prevent future accelerated viral in-
972 fection similar to COVID. *The Science of the total environment* **2020**, *729*, 138474.
973 <https://doi.org/10.1016/j.scitotenv.2020.138474>
- 974 165. Lim, Y.K.; Kweon, O.J.; Kim, H. R.; Kim, T.H.; Lee, M.K. The impact of environmental variables on the spread of
975 COVID-19 in the Republic of Korea. *Scientific reports* **2021**, *11*(1), 5977. <https://doi.org/10.1038/s41598-021-85493-y>
- 976 166. Azuma, K.; Yanagi, U.; Kagi, N.; Kim, H.; Ogata, M.; Hayashi, M. Environmental factors involved in SARS-CoV-2 trans-
977 mission: effect and role of indoor environmental quality in the strategy for COVID-19 infection control. *Environmental
978 health and preventive medicine* **2020**, *25*(1), 66. <https://doi.org/10.1186/s12199-020-00904-2>
- 979 167. Greenhalgh, T.; Jimenez, J.L.; Prather, K.A.; Tufekci, Z.; Fisman, D.; Schooley, R. Ten scientific reasons in support of air-
980 borne transmission of SARS-CoV-2. *The Lancet* **2021**, *397*(10285), 1603–1605. [https://doi.org/10.1016/S0140-6736\(21\)00869-2](https://doi.org/10.1016/S0140-6736(21)00869-2)
- 981 168. Huang, C.; Huang, L.; Wang, Y.; Li, X.; Ren, L.; Gu, X. et al. 6-month consequences of COVID-19 in patients discharged
982 from hospital: a cohort study. *The Lancet* **2021**, *397*(10270), 220–232. [https://doi.org/10.1016/S0140-6736\(20\)32656-8](https://doi.org/10.1016/S0140-6736(20)32656-8)
- 983 169. Patel, M.; Chaubey, A.K.; Pittman, C.U.; Jr, Mlsna, T.; Mohan, D. Coronavirus (SARS-CoV-2) in the environment: Occur-
984 rence, persistence, analysis in aquatic systems and possible management. *The Science of the total environment* **2021**, *765*,
985 142698. <https://doi.org/10.1016/j.scitotenv.2020.142698>